irinotecan has been researched along with Diarrhea in 448 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 61 (13.62) | 18.2507 |
| 2000's | 208 (46.43) | 29.6817 |
| 2010's | 134 (29.91) | 24.3611 |
| 2020's | 45 (10.04) | 2.80 |
| Authors | Studies |
|---|---|
| Páez, D; Riera, P | 1 |
| Chen, D; Gao, F; Kan, S; Lu, C; Qian, Z; Yin, Y; Zhu, H | 1 |
| Bekaii-Saab, T; Boland, PM; Brendel, K; Dayyani, F; Dean, A; Macarulla, T; Maxwell, F; Mody, K; Pedret-Dunn, A; Wainberg, ZA; Zhang, B | 1 |
| Agarwal, N; Mathew Thomas, V; Swami, U; Tripathi, N | 1 |
| Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S | 1 |
| Chityala, PK; Ghose, R; Li, L; Lin, Z; Tao, G | 1 |
| Atasilp, C; Biswas, M; Hongkaew, Y; Jinda, P; Nuntharadthanaphong, N; Rachanakul, J; Saokaew, S; Sukasem, C; Vanwong, N | 1 |
| Chen, Z; Jiang, Y; Song, B | 1 |
| Antunes, MV; Basso, J; Hahn, RZ; Ibaldi, MR; Linden, R; Pavei, CC; Schaefer, VD; Schwartsmann, G | 1 |
| Ikushiro, S; Maruo, Y; Mimura, Y; Tagawa, K | 1 |
| Dahlgren, D; Hellström, PM; Kullenberg, F; Lennernäs, H; Nygren, P; Peters, K; Rosenqvist, E; Sjöblom, M | 1 |
| Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M | 1 |
| Huang, K; Huang, Y; Jin, H; Li, M; Tan, B; Wang, J; Yin, Y; Yuan, D | 1 |
| Ahmed, KA; Aidy, SE; Azmy, AF; Dishisha, T; El-Gendy, AO; Hassan, A; Mahdy, MS; Mohamed, WR | 1 |
| Bates, SE; Connolly, RM; Gano, K; LaRose, M; O'Sullivan, CC; Pommier, Y; Thomas, A; Velcheti, V; Vilimas, R | 1 |
| Broudin, C; Gallois, C; Jenvrin, A; Palmieri, LJ; Perret, A; Rance, B; Soularue, E; Taieb, J | 1 |
| Fukuda, M; Hosoe, T; Ikarashi, N; Kamei, J; Kon, R; Miyaoka, K; Noguchi, H; Sakai, H; Teshima, Y; Tomimoto, R; Yamaguchi, A; Yamaguchi, T | 1 |
| Cao, Z; Chen, L; Chen, S; Chen, Y; Huang, W; Jiao, S; Li, Z; Liu, Y; Mao, J; Wang, W; Yang, Z; Zhang, L | 1 |
| Cao, Z; Chen, L; Chen, S; Chen, Y; Huang, W; Jiao, S; Li, Z; Liu, Y; Sun, L; Wang, W; Yang, Z; Zhang, L | 1 |
| Deng, H; Dou, W; Pan, Y; Wang, Y; Xiao, L; Xu, H | 1 |
| Fu, Y; Liang, Z; Liu, B; Liu, Z; Qiu, H; Sun, R; Teng, X; Wang, C; Xu, X; Zhang, L; Zhang, R; Zhou, R; Zhu, L | 1 |
| Pei, J; Wang, Y; Zhou, W; Zou, Y | 1 |
| Basu, S; Gao, S; Ghose, R; Hu, M; Li, L; Liu, Z; Sun, R; Sunsong, R; Wang, W; Zeng, M | 1 |
| Huang, H; Jiang, W; Jinbo, M; Wang, H; Wang, X; Yu, P; Zhang, G; Zhang, X | 1 |
| Chang, S; Chen, Z; Kong, R; Liu, J; Piao, L; Xu, X | 1 |
| Ahn, D; Barzi, A; Bekaii-Saab, T; Corvino, FA; Mamlouk, K; Miksad, R; Pulgar, S; Surinach, A; Torres, AZ; Valderrama, A; Wang, S | 1 |
| Abe, S; Hatano, A; Ikeda, Y; Izumi, T; Miyamoto, L; Okuno, H; Tsuchihashi, Y; Tsuchiya, K; Tsunematsu, H; Yamane, M; Yasuoka, T | 1 |
| Ai, Q; Edirisuriya, P; Sun, S; Yang, F; Zhou, K; Zhu, W | 1 |
| Hoogeman, M; Loi, M; Magallon-Baro, A; Nuyttens, JJ; Suker, M; Van Eijck, C | 1 |
| Fan, J; Li, C; Wan, J; Wang, J; Yang, L; Zhang, H; Zhang, Z; Zhu, J | 1 |
| Deng, B; Deng, C; Gao, Y; Jia, L; Lou, Y; Su, F | 1 |
| Gao, S; Ghose, R; Gong, X; Hu, M; Li, L; Liu, Z; Qi, X; Song, W; Sun, R; Wang, Y; Zhu, L | 1 |
| Acharya, A; Amin, M; Copsey, ML; Gao, F; Jin, RU; Lim, KH; Lockhart, AC; Morton, AE; Navo, KA; Park, H; Pedersen, KS; Rigden, C; Suresh, R; Tan, BR; Trikalinos, NA; Wang-Gillam, A | 1 |
| Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S | 1 |
| Ma, R; Ma, X; Yang, G; Zhu, X | 1 |
| Chang, XY; Dong, L; Jiang, ZP; Jin, WY; Li, ZZ; Shi, JW; Shi, Y; Sun, H; Wu, JS | 1 |
| Chai, K; Chen, J; Chen, L; Chen, M; Dong, C; Hu, X; Li, R; Lu, Y; Shi, S; Sun, Y; Wang, C; Yao, T; Zhou, L | 1 |
| de Bruijn, P; de Bruin, RWF; de Man, FM; Dollé, MET; IJzermans, JNM; Koolen, SLW; Lolkema, MP; Mathijssen, RHJ; Moelker, A; Olieman, JF; Oomen-de Hoop, E; Sandberg, Y; van Doorn, GM; van Eerden, RAG; van Gelder, T; van Halteren, HK; Veraart, JN | 1 |
| Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R | 1 |
| Borgonovo, K; Cabiddu, M; Ghidini, M; Ghilardi, M; Lonati, V; Nicoletti, M; Parati, MC; Petrelli, F; Ratti, M; Tomasello, G | 1 |
| Burnouf, PA; Chen, BM; Chen, CY; Dashnyam, P; Gao, S; Hsieh, TJ; Hsieh, WC; Kuo, YH; Lin, CH; Lin, HY; Lin, TC; Roffler, SR; Tu, Z; Yeh, LF | 1 |
| Chen, Z; Jia, Y; Wang, P; Wu, R; Yan, R | 1 |
| Cheng, Y; Fu, C; Hu, Y; Wang, D; Wu, Y; Yang, X; Yang, Y; Zhang, J | 1 |
| Chang, TK; Chen, PJ; Chen, YC; Cheng, TL; Chuang, KH; Huang, CW; Li, CC; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yin, TC | 1 |
| Almeida, PRC; Amorim, JO; Arruda, LM; Bandeira, AM; Cajado, AG; Carvalho, RF; Chaves, FF; Cunha, FQ; Ferreira, LMM; Holanda, RBF; Lima-Júnior, RCP; Lopes, MHS; Oliveira, RTG; Pereira, AF; Pereira, JFB; Pinheiro, RF; Ribeiro-Júnior, HL; Rocha-Filho, DR; Sant'Ana, RO; Torres, CS; Wong, DVT | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Kashihara, H; Kono, T; Kurita, N; Shimada, M; Takasu, C; Yismaw, WG; Yoshikawa, K | 1 |
| Sahota, S; Vahdat, LT | 1 |
| Kalluri, R; Kurywchak, P | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Gao, J; Li, J; Li, Y; Liu, D; Shen, L; Yang, R | 1 |
| Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L | 1 |
| Adam, R; Boige, V; Bouchahda, M; Carvalho, C; Desterke, C; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Lemoine, A; Lévi, F; Milano, G; Saffroy, R; Smith, D; Taieb, J | 1 |
| Duan, Z; Pan, D; Peng, H; Wei, X; Wen, J | 1 |
| Chen, YL; Cheng, KW; Cheng, TC; Cheng, TL; Chuang, YC; Leu, YL; Lu, YC; Tseng, CH; Tzeng, CC; Wang, JY; Yang, CN | 1 |
| Almeida, PRC; Câmara, LMC; Cândido, AGF; Falcão, RB; Fernandes, C; Lima-Júnior, RCP; Muniz, HA; Silva, CMS; Souza, MHLP; Souza, NRP; Teixeira, MA; Wanderley, CWS | 1 |
| Fujikawa, T; Ikarashi, N; Kato, S; Kimura, H; Kon, R; Machida, Y; Matsunaga, Y; Minami, M; Murakami, Y; Sakurai, R; Sugiyama, K; Tomimoto, R; Tsubota, Y | 1 |
| Abe, T; Baba, J; Hirata, A; Ichikawa, K; Kikuchi, T; Kondo, R; Koya, T; Makino, M; Maruyama, Y; Sato, K; Shoji, S; Tanaka, H; Tanaka, J; Terada, M; Tsukada, H; Watanabe, S; Yoshizawa, H | 1 |
| Barnadas, A; Gallano, P; Páez, D; Riera, P; Salazar, J; Sebio, A; Tobeña, M; Virgili, AC | 1 |
| Honda, M; Kim, HM; Kondo, K; Kosugi, C; Matsuda, C; Mishima, H; Oba, K; Sakamoto, J; Takahashi, T; Takemoto, H; Tanaka, C; Tokunaga, Y | 1 |
| Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T | 1 |
| Bosman, F; Brauchli, P; Delorenzi, M; Dietrich, D; Fiocca, R; Klingbiel, D; Piessevaux, H; Roth, AD; Tejpar, S; Yan, P | 1 |
| Gao, S; Ghose, R; Hu, M; Ittmann, MM; Mallick, P; Shah, P; Trivedi, M | 1 |
| Cui, Y; Hu, M; Huang, F; Liang, L; Yang, Y; Zhong, Q; Zhou, M | 1 |
| Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L | 1 |
| Kawano, K; Matsukuma, K; Nasu, H; Nishio, S; Shimokawa, M; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T | 1 |
| Chuma, M; Fujino, H; Fukushima, K; Hamano, H; Horinouchi, Y; Ikeda, Y; Imanishi, M; Ishizawa, K; Izawa-Ishizawa, Y; Kirino, Y; Mitsui, M; Nakamura, T; Nimura, T; Okada, N; Takechi, K; Tamaki, T; Teraoka, K; Yanagawa, H; Zamami, Y | 1 |
| Gong, L; Han, N; Li, C; Lu, H; Qin, J; Xie, F | 1 |
| Fujita, KI; Ishida, H; Iwai, S; Kamei, D; Kubota, Y; Sasaki, Y; Taki-Takemoto, I; Tsuboya, A | 1 |
| Bowen, JM; Coller, JK; Fakiha, K; Gibson, RJ; Logan, RM | 1 |
| Chang, JM; Chen, IJ; Chen, YL; Cheng, CM; Cheng, KW; Cheng, TC; Cheng, TL; Cheng, YA; Leu, YL; Lu, YC; Tseng, CH; Tzeng, CC; Wang, JY | 1 |
| Liu, JZ; Liu, WW; Liu, ZL; Wang, B | 1 |
| Fu, C; Wang, D; Wu, Y; Yang, X; Zhang, J; Zou, L | 1 |
| Abramson, VG; Bardia, A; Diamond, JR; Goldenberg, DM; Iannone, R; Isakoff, SJ; Kalinsky, K; Mayer, IA; Moroose, RL; O'Shaughnessy, J; Rugo, HS; Santin, AD; Shah, NC; Sharkey, RM; Sweidan, AM; Tolaney, SM; Vahdat, LT; Washkowitz, S; Wegener, WA | 1 |
| Armand, JP; Chamseddine, AN; Ducreux, M; Mir, O; Paci, A; Paoletti, X; Satar, T | 1 |
| Lu, Y; Luo, Z; Ouyang, M; Wu, J; Yao, X; Zhang, W; Zhu, D | 1 |
| Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O | 1 |
| Chen, S; Feng, M; Guo, S; Hou, Q; Liu, Y; Pan, Y; Sun, L; Wang, P; Wang, Y; Xu, H; Yue, T | 1 |
| Alonso, B; Aranda, E; Arrivi, A; Bando, I; Carrato, A; Conde, V; Díaz-Rubio, E; Elez, E; Gallego, J; Grávalos, C; López, C; Ortiz, MJ; Pericay, C; Ruiz de Mena, I; Safont, MJ; Tabernero, J; Valladares-Ayerbes, M | 1 |
| Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A | 1 |
| Cheng, D; Kuang, Q; Liu, G; Liu, X; Xu, W | 1 |
| Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J | 1 |
| Goel, S; Mani, S; Swami, U | 1 |
| Filip, S; Grim, J; Paulík, A | 1 |
| Gao, J; Jia, R; Li, Y; Lu, M; Shen, L; Zhou, J | 1 |
| Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM | 1 |
| Blake, D; Bridgewater, J; Brown, S; Chau, I; Gollins, S; Gwyther, S; Hill, M; Lowe, C; Maisey, N; Marshall, H; Maughan, T; Middleton, G; Myint, S; Napp, V; Oliver, A; Richman, S; Seymour, M; Slater, S; Wadsley, J; Wagstaff, J | 1 |
| Xu, JM | 1 |
| Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA | 1 |
| Brutcher, E; Chen, Z; El-Rayes, BF; Hawk, N; Kauh, J; Kim, S; Kooby, DA; Landry, J; Mahaseth, H; Maithel, SK | 1 |
| Al-Dasooqi, N; Bateman, E; Bowen, JM; Gibson, RJ; Shirren, J; Stansborough, R; Sultani, M; Wardill, HR | 1 |
| Hamada, A; Harada, T; Kudoh, S; Maeno, K; Miyawaki, H; Moriyama, A; Nakagawa, K; Nakanishi, Y; Saeki, S; Shimokawa, M; Takayama, K | 1 |
| Ikegami, Y; Inoue, Y; Ishikawa, T; Nakagawa, H; Nakamura, Y; Sano, K; Suzuki, T; Yoshida, H | 1 |
| Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B | 1 |
| Benson, AB; Berlin, J; Burtness, B; Catalano, P; Chapman, AE; Liles, DK; Mitchell, E; Powell, M | 1 |
| Doherty, GA; Lee, CS; Ryan, EJ | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wang, L; Wu, XY; Xiang, J | 1 |
| Barni, S; Borgonovo, K; Coinu, A; Ghidini, A; Petrelli, F | 1 |
| Ema, A; Naito, M; Nakamura, T; Sato, T; Watanabe, M; Yamashita, K | 1 |
| Bayraktar, S; Broome, P; de Queiroz Marques Junior, E; Leslie, M; Nowacki, M; Rocha-Lima, CM; Susnerwala, S; Weissman, C | 1 |
| Goto, K; Matsumoto, S; Morise, M; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K | 1 |
| Anantha, M; Bally, MB; Harasym, N; Manisali, I; Masin, D; Osooly, M; Ostlund, C; Santos, ND; Strutt, D; Sutherland, BW; Waterhouse, DN; Webb, MS; Wehbe, M | 1 |
| Doi, A; Doi, T; Hamaguchi, T; Ichinohe, R; Kaniwa, N; Matsumura, Y; Odaka, Y; Ohtsu, A; Okuda, H; Okuyama, M; Sai, K; Saijo, N; Saito, Y; Sakamoto, H; Sawada, J; Shimada, Y; Takahashi, A; Takahashi, H; Yoshida, T; Yoshino, T | 1 |
| Crocenzi, T; Esparaz, B; Fisch, MJ; Glover, K; Jones, D; Kee, BK; Morris, JS; Overman, M; Slack, RS; Wen, S; Wong, L | 1 |
| Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K | 1 |
| Hofheinz, RD; Khazzaka, E; Mai, S; Reis, T; Welzel, G; Wenz, F | 1 |
| Arora, K; Buddington, RK; de Jonge, HR; Moon, C; Naren, AP; Parthasarathi, K; Ren, A; Schuetz, JD; Shanmukhappa, SK; Shata, MT; Sinha, C; Valasani, KR; Woodrooffe, K; Yarlagadda, S; Zhang, W | 1 |
| Chen, Y; Cheng, Y; Jiang, H; Ma, L; Yang, C; Zhu, J | 1 |
| Beniak, J; Bystricky, B; Chovanec, J; Drgona, L; Konkolovsky, P; Lagin, A; Mardiak, J; Medvecova, L; Mego, M; Mikulova, M; Miskovska, V; Reckova, M; Spanik, S; Svetlovska, D; Vochyanova-Andrezalova, I; Zajac, V | 1 |
| Bateman, E; Keefe, D; Klein, G; Mayo, B; Plews, E; Weaver, E; White, I; Wignall, A; Wozniak, B | 1 |
| Inoue, A; Ishimoto, O; Maemondo, M; Nukiwa, T; Sugawara, S | 1 |
| Ding, YY; Song, LX; Xu, JF; Xu, Q | 1 |
| Chang, GJ; Crane, CH; Das, P; Feig, BW; Krishnan, S; Minsky, BD; Rashid, A; Skibber, JM; Voong, KR; Wolff, RA; Yao, JC | 1 |
| de Bruijn, P; de Bruin, RW; Ghobadi Moghaddam-Helmantel, IM; Huisman, SA; IJzermans, JN; Mathijssen, RH; Wiemer, EA | 1 |
| Cecchin, E; Chen, S; Couture, F; Guillemette, C; Innocenti, F; Jonker, D; Laverdière, I; Lévesque, E; Toffoli, G; Villeneuve, L | 1 |
| Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ | 1 |
| Arzt, J; Busman, TA; Holen, KD; Lian, G; LoRusso, P; Rosen, LS; Rudersdorf, NS; Tolcher, AW; Vanderwal, CA; Waring, JF; Yang, J | 1 |
| Gu, Y; Li, L; Li, Q; Wang, W; Wu, X; Xu, Q; Zhang, X | 1 |
| Almeida, PR; Batista, GL; Bem, AX; Borges, VF; Brito, GA; Carvalho, CB; Cunha, FQ; Cunha, TM; Leite, CA; Lima-Júnior, RC; Ribeiro, RA; Silva, RL; Teixeira, MA; Wanderley, CW; Wong, DV | 1 |
| Fujita, D; Nakanishi, T; Saito, Y; Tamai, I | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Almeida, PR; Assis-Júnior, EM; Brito, GA; Lima-Júnior, RC; Melo, AT; Pereira, VB; Ribeiro, RA; Wong, DV | 1 |
| Deng, B; Jia, LQ; Pan, L; Tan, HY; Wang, J; Yu, LL | 1 |
| Liu, JY; Nie, YL; Wang, XF; Wei, LM; Yan, L; Zhang, LR | 1 |
| Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N | 1 |
| Cai, Y; Chen, J; Feng, J; Fu, Q; Fu, S; Hong, Q; Huang, L; Li, J; Liu, S; Xie, C; Xu, M; Yu, Q; Yuan, X; Zang, A; Zhang, M; Zhang, T | 1 |
| Jensen, HA; Krogh, M; Pfeiffer, P; Qvortrup, C; Sorbye, H; Vestermark, LW; Winther, SB; Zubcevic, K | 1 |
| Baba, H; Hayakawa, K; Hiraoka, M; Ikushima, H; Kamikonya, N; Kato, D; Nemoto-Murofushi, K; Noda, M; Oya, M; Oya, N; Sakai, Y; Sato, T; Shimada, M; Takeuchi, M; Tomita, N; Watanabe, M; Watanabe, T | 1 |
| Bateman, E; Bowen, JM; Campbell, JM; Keefe, DM; Peters, MD; Stephenson, MD | 1 |
| Forsgård, RA; Frias, R; Holma, R; Korpela, R; Lindén, J; Österlund, P; Spillmann, T | 1 |
| Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C | 1 |
| Ball, IA; Bowen, JM; Coller, JK; Gibson, RJ; Lightwala, Z; Secombe, K; Shirren, J; Stansborough, RL; van Sebille, YZ; Wardill, HR; Wignall, A | 1 |
| Qin, HY; Shi, AX; Wang, YP; Wu, XA; Zhang, XY; Zhao, YS; Zhou, Y | 1 |
| Davies, A; Gandara, D; Huynh, M; Johl, J; Lara, P; Lau, D; Tanaka, M | 1 |
| Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B | 1 |
| Gelderblom, H; Guchelaar, HJ; Kweekel, D | 1 |
| Miya, T; Morimoto, Y; Ooi, K; Sasaki, H | 1 |
| Anthony, L | 1 |
| Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M | 1 |
| Deeken, JF; Marshall, JL; Slack, R | 1 |
| Nariai, H; Natsumeda, T; Oto, Y; Sato, Y; Shitara, T; Taniuchi, M | 1 |
| Asahara, T; Fukui, T; Iwasaki, M; Katono, K; Kurita, A; Masuda, N; Mitsufuji, H; Nishii, Y; Onoda, S; Ryuge, S; Takakura, A; Wada, M; Yamamoto, M; Yanaihara, T; Yokoba, M | 1 |
| Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J | 1 |
| Bowen, JM; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM; Yeoh, AS | 1 |
| Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Masuzawa, T; Mishima, H; Nakamori, S; Takeda, M; Tsujinaka, T | 1 |
| Cicin, I; Sezer, A; Usta, U | 1 |
| Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C | 1 |
| Ilson, DH; Kelsen, DP; Ku, GY; Maki, RG; O'Reilly, EM; Saltz, LB; Schrag, D | 1 |
| Baracos, VE; Dieleman, LA; Field, CJ; Le Roy, S; Sawyer, MB; Xue, H | 1 |
| Carleton, JE; Chansky, K; Crowley, J; Dakhil, SR; Gandara, DR; Jett, J; Kuebler, JP; Langer, CJ; Lara, PN; Lenz, HJ; Natale, R; Redman, MW | 1 |
| Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL | 1 |
| Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E | 1 |
| Baracos, VE; Dieleman, LA; Field, CJ; Sawyer, MB; Xue, H | 2 |
| Blackhall, FH; Ferraldeschi, R; Hadfield, KD; Minchell, LJ; Mullamitha, S; Newman, WG; Roberts, SA; Saunders, M; Tobi, S; Valle, J; Wilson, G | 1 |
| Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH | 1 |
| Al-Dasooqi, N; Ashton, K; Bowen, JM; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM; Yeoh, AS | 1 |
| Cunningham, D; Yim, KL | 1 |
| Glisson, BS; Johnson, FM | 1 |
| Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I | 1 |
| Boeck, S; Giessen, C; Heinemann, V; Moosmann, N; Schalhorn, A; Schulz, C; Stemmler, HJ; Zwingers, T | 1 |
| Chen, XX; Guo, GF; Hu, PL; Jiang, WQ; Liu, MZ; Qiu, HJ; Xia, LP; Zhang, B; Zhou, FF | 1 |
| Attinà, G; Coccia, P; Riccardi, R; Ruggiero, A; Scalzone, M | 1 |
| Ahn, BJ; Choi, MK; Heo, JS; Kang, WK; Kim, S; Lee, J; Lim, HY; Noh, JH; Park, JO; Park, SH; Park, YS; Sohn, TS; Yim, DS | 1 |
| Brown, TJ; Clavant, SP; Clingan, PR; Fox, RM; Ganju, V; Gibbs, P; Leung, J; Pho, M; Strickland, AH; Tebbutt, NC; Underhill, CR; Wong, SS | 1 |
| Hu, ZY; Yu, Q; Zhao, YS | 1 |
| Asakawa, N; Kado, S; Kaneda, N; Kato, I; Kurita, A; Matsumoto, T; Onoue, M; Uchida, K; Yokokura, T | 1 |
| Alonso, V; Antón, I; Arrivi, A; Cirera, L; Constenla, M; Escudero, P; García, P; Grande, C; Guasch, I; López, LJ; Losa, F; Martin, C; Méndez, M; Moreno, I; Pericay, C; Quintero-Aldana, G; Roca, JM; Salud, A; Vicente, P; Yubero, A | 1 |
| Fushimi, K; Kumagai, K; Nakano, S; Yamamoto, N | 1 |
| Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW | 1 |
| Campanella, C; Cognetti, F; Ettorre, GM; Garufi, C; Mottolese, M; Sperduti, I; Torsello, A; Tumolo, S; Vennarecci, G; Zeuli, M | 1 |
| Hatate, K; Hayakawa, K; Ihara, A; Koizumi, W; Naito, M; Nakamura, T; Okayasu, I; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamashita, K | 1 |
| Jobin, C; Koo, JS; Lane, KT; Mani, S; Orans, J; Redinbo, MR; Scott, JE; Venkatesh, M; Wallace, BD; Wang, H; Yeh, LA | 1 |
| Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S | 1 |
| Guo, GF; Jiang, WQ; Qiu, HJ; Wang, F; Xia, LP; Xu, RH; Zhang, B; Zhou, FF | 1 |
| Ge, FJ; Li, SS; Li, ZQ; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH | 1 |
| Iwata, T; Komatsu, M; Kurita, N; Nakao, T; Shimada, M; Utusnomiya, T; Yoshikawa, K | 1 |
| Chon, HJ; Chung, HC; Jeung, HC; Kim, HS; Noh, SH; Park, HS; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Farndon, P; Li-Wan-Po, A | 1 |
| Crews, KR; Furman, WL; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Tagen, M; Wozniak, A; Wu, J | 1 |
| Chen, DY; Qi, Q; Zhao, WY | 1 |
| Ahn, JB; Hong, YS; Kim, SH; Kim, SY; Kim, TW; Lee, KH; Lee, SH; Park, SH; Park, YS; Shin, SJ | 1 |
| Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM | 1 |
| Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J | 1 |
| Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T | 1 |
| Ariyoshi, Y; Fukuoka, M; Kakihata, K; Masatani, S; Sakata, Y; Shimazaki, M; Shiozawa, T; Tadokoro, J; Yamaguchi, F | 1 |
| Agostini, V; Biasco, G; Bolondi, L; Borghi, A; Brandi, G; Cappelli, A; Costantini, S; Danesi, R; Derenzini, E; Di Paolo, A; Fanello, S; Giampalma, E; Golfieri, R; Mirarchi, MG; Pini, P; Piscaglia, F | 1 |
| Deepak, P; Ehrenpreis, ED | 1 |
| Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY | 1 |
| Chikakiyo, M; Higashijima, J; Iwata, T; Kurita, N; Nakao, T; Nishioka, M; Shimada, M; Yoshikawa, K | 1 |
| Huang, H; Li, H; Liu, JH | 1 |
| Conibear, J; Raouf, S; Tarver, K | 1 |
| Abdel-Aziz, H; Abdelwahab, S; Azmy, A; Mahmoud, A; Salim, H | 1 |
| Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S | 1 |
| Bufill, J; Burns, M; Cardenes, H; Chiorean, EG; Clark, R; Coleman, N; Curie, C; Hinkle, DT; LeBlanc, J; Loehrer, PJ; Robb, B; Sanghani, S; Schiel, MA; Tong, Y; Yu, M | 1 |
| Fujita, K; Ishida, H; Kato, Y; Miwa, K; Saji, S; Sasaki, T; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Ghang, HY; Han, JY; Hwang, JA; Kim, JY; Kim, SY; Lee, JS; Lee, YS; Shin, ES | 1 |
| Dias, MM; McKinnon, RA; Sorich, MJ | 1 |
| Brock, P; Brugières, L; Casanova, M; Child, M; Czauderna, P; de Camargo, B; Maibach, R; Morland, B; Pariente, D; Paris, C; Perilongo, G; Plaschkes, J; Roebuck, D; Ronghe, M; Zimmermann, A; Zsíros, J | 1 |
| Bradbury, J; Cave, J; Crabb, SJ; Johnson, PW; Muthuramalingam, SR; Nolan, L; Ottensmeier, C; Selman, D | 1 |
| Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| Andoh, A; Shioya, M | 1 |
| Kawabe, Y; Mori, N; Murakami, T; Yokooji, T | 1 |
| Chen, DY; Zhao, WY | 1 |
| Etoh, T; Hayashi, H; Inoue, K; Itoh, K; Kawamura, Y; Kikuyama, M; Kimura, M; Matsumura, T; Minami, S; Sonobe, M; Suzuki, T; Takagi, M; Tsuji, D; Utsuki, H; Yamazaki, T | 1 |
| Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M | 1 |
| Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA | 1 |
| Gan, Y; Guo, SY; Li, FF; Zhang, XX | 1 |
| Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Akiyama, Y; Handa, S; Kobayashi, K; Kudo, K; Kudoh, S; Soma, T; Takeda, Y | 2 |
| Karlsson, MO; Mathijssen, RH; Sparreboom, A; Verweij, J; Xie, R | 1 |
| Antonellini, A; Elfring, GL; Gillenwater, HH; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Sandler, AB; Socinski, MA | 1 |
| Fujii, H; Konishi, M; Koshiyama, M; Tauchi, K; Yoshida, M | 1 |
| Adams, AL; Brady, D; Engstrom, PF; Gallo, JM; Kilpatrick, D; Lewis, NL; Litwin, S; Meropol, NJ; Scher, R; Szarka, CE; Weiner, LM | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA | 1 |
| Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE | 1 |
| Davis, TW; Durham, WF; Horton, J; Levine, BD; Masferrer, JL; Salazar, VS; Trifan, OC; Zweifel, BS | 1 |
| Borel, C; Caroli-Bosc, FX; Couteau, C; Desseigne, F; Hua, A; Jacob, JH; Kramar, A; Lefebvre, P; Merrouche, Y; Raoul, JL; Seitz, JF; Ychou, M | 1 |
| Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT | 1 |
| Rothenberg, ML | 1 |
| Ma, MK; McLeod, HL | 1 |
| Aoki, F; Kaminishi, M; Mafune, K; Shimizu, N; Shimoyama, S; Tatsutomi, Y | 1 |
| Farrell, MP; Kummar, S | 1 |
| Eguchi, K; Goto, K; Hojo, F; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yoshimura, K | 1 |
| Kamiyama, Y; Kano, Y; Kondo, T; Mori, K; Tominaga, K | 1 |
| Alimonti, A; Burattini, E; Pavese, I; Satta, F; Vecchione, A; Zoffoli, V | 1 |
| Balram, C; Cheung, YB; Lee, EJ; Zhou, QY | 1 |
| Kobayashi, K | 1 |
| Hashimoto, S; Kado, S; Kaneda, N; Kurita, A; Onoue, M; Yokokura, T | 2 |
| Bowen, JM; Cummins, AG; Gibson, RJ; Inglis, MR; Keefe, DM | 1 |
| Bittorf, B; Brueckl, V; Brueckl, WM; Hahn, EG; Hegewald, J; Hohenberger, W; Jüngert, B; Männlein, G; Mühldorfer, S; Schirner, I; Stickel, F; Wein, A | 1 |
| Bourhis, JH; Carde, P; Fermé, C; Koscielny, S; Munck, JN; Ribrag, V; Rideller, K; Vantelon, JM | 1 |
| Shirao, K; Ura, T | 1 |
| Eguchi, K; Kobayashi, K; Matsumoto, T; Morita, S; Ohashi, Y; Sakamoto, J; Shibuya, M; Yamaji, Y | 1 |
| Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J | 1 |
| Viele, CS | 1 |
| Ariyoshi, Y; Fukuoka, M; Hoso, T; Katakami, N; Kawahara, M; Kudoh, S; Matsui, K; Nakagawa, K; Nakano, T; Negoro, SI; Saito, H; Senba, H; Sugiura, T; Takada, Y; Yamamoto, N | 1 |
| Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G | 1 |
| Bafaloukos, D; Bamias, A; Economopulos, T; Fountzilas, G; Janinis, J; Kalofonos, HP; Kouvatseas, G; Papakostas, P; Skarlos, D; Stavropoulos, M; Timotheadou, E | 1 |
| Alpaugh, RK; Cohen, SJ; Gallo, J; Gentner, L; Lewis, NL; Meropol, NJ; Palmer, PA; Rogatko, A; Schol, J; Verhaeghe, T; Weiner, LM; Yeslow, G; Zannikos, P | 1 |
| Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G | 1 |
| Beroza, P; Damodaran, K; Danks, MK; Hyatt, JL; Lee, RE; Morton, CL; Potter, PM; Wadkins, RM; Yoon, KJ | 1 |
| Fittkau, M; Holzhausen, HJ; Schmoll, HJ; Voigt, W | 1 |
| Kullmann, F; Schölmerich, J; Schultz, M | 1 |
| Gemba, K; Harita, S; Kamei, H; Kiura, K; Nogami, N; Segawa, Y; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Bereder, JM; Bernardini, D; Cals, L; Deplanque, G; Favre, R; François, E; Herait, P; Juin, P; Laadem, A; Merad, L; Rixe, O | 1 |
| Holcombe, RF; Kong, KM; Wimmer, D | 1 |
| Grothey, A; Jordan, K; Kegel, T; Kellner, O; Schmoll, HJ | 1 |
| Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J | 1 |
| Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C | 1 |
| Jahnke, K; Keilholz, U; Schmittel, A; Thiel, E | 1 |
| Altés, A; Baiget, M; Del Rio, E; Gómez-Pardo, M; Marcuello, E; Menoyo, A | 1 |
| Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D | 1 |
| Kiribayashi, Y; Maeda, Y; Murakami, T; Nakamura, M; Ohune, T; Yamasaki, M | 1 |
| Aliustaoglu, M; Aydin, SZ; Dane, F; Ekenel, M; Gumus, M; Karamanoglu, A; Sengoz, M; Turhal, SN; Yumuk, PF | 1 |
| Alimonti, A; Cognetti, F; Di Palma, M; Ferretti, G; Gelibter, A; Pavese, I; Rasio, D; Satta, F; Vecchione, A | 1 |
| Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A | 1 |
| Cisar, LA; Green, MR; Gruia, G; Jeffrey, GM; Miller, LL; Miller, WH; Morganti, A; Orlando, N; Rocha Lima, CM; Rotche, R | 1 |
| Briasoulis, E; Fountzilas, G; Pavlidis, N; Pentheroudakis, G; Rammou, D; Timotheadou, H | 1 |
| Brittain, M; Feld, R; Hedley, D; Michael, M; Moore, MJ; Nagai, J; Oza, A; Siu, L | 1 |
| Cheung, YB; Chowbay, B; Leong, SS; Poon, D; Tan, EH | 1 |
| Govindan, R; McLeod, H; Read, W | 1 |
| Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H | 1 |
| Aoyama, N; Hamano, K; Hirohata, S; Horita, K; Ishii, A; Kamigaki, T; Kasuga, M; Nakashima, T; Nishisaki, H; Shirasaka, D; Tamura, T; Yasutake, K | 1 |
| Assadourian, S; de Jong, FA; de Jonge, MJ; Dumez, H; Eskens, FA; Lefebvre, P; Sanderink, GJ; Selleslach, J; Soepenberg, O; Sparreboom, A; Ter Steeg, J; Thomas, J; van Oosterom, AT; van Schaik, RH; Verweij, J | 1 |
| Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M | 1 |
| Bowen, JM; Gibson, RJ; Keefe, DM | 1 |
| Aparicio, J; Balcells, M; Bosch, C; Busquier, I; Campos, JM; Galán, A; Garcerá, S; Llorca, C; López-Tendero, P; Maestu, I; Vicent, JM | 1 |
| Bouzourene, H; Chaubert, P; Sandmeier, D | 1 |
| Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML | 1 |
| Chung, G; Mehra, R; Murren, J; Psyrri, A; Smith, B | 1 |
| Fioravanti, S; Grem, JL; Guo, X; Harold, N; Hopkins, JL; Leguizamo, JP; Leonard, GD; Lin, P; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Wright, MA | 1 |
| Chan, E; Chan, SY; Chen, X; Duan, W; Ho, PC; Hu, Z; Huang, M; Li, X; Xu, C; Yang, H; Yang, X; Zhou, S; Zhu, YZ | 1 |
| Chan, E; Chan, SY; Duan, W; Goh, BC; Hu, Z; Yang, X; Zhou, S | 1 |
| Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP | 1 |
| Beale, P; Clarke, S; Liddell, S; Noney, L; Rivory, LP; Tobin, PJ | 1 |
| Abenhardt, W; Ballo, H; Behrens, R; Behringer, D; Boeck, HP; Braumann, D; Geer, T; Greinwald, R; Karthaus, M; Kindler, M; Kleeberg, U; Messmann, H; Schimke, J; Steinmetz, T | 1 |
| Aoki, A; Hamada, A; Ito, K; Saito, H; Sasaki, Y; Terazaki, H; Yokoo, K | 1 |
| Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G | 1 |
| Ahn, JS; Chang, HM; Kang, WK; Kang, YK; Kim, HK; Kim, SR; Kim, TW; Lee, KH; Park, JO; Ryoo, BY; Zang, DY | 1 |
| Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J | 1 |
| Han, JY; Kim, EA; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Park, CG; Yoon, SM | 1 |
| Hasegawa, Y; Ishikawa, K; Kajita, Y; Nabeshima, T; Noda, Y; Yoshida, J | 1 |
| Fung, A; Viale, PH; Zitella, L | 1 |
| Andersen, N; Brandt, D; Davies, MJ; Murren, JR; Nadkarni, R; Parisot, N; Pizzorno, G; Psyrri, D; Rose, M; Rosenfield, AT; Zelterman, D | 1 |
| Ando, M; Ando, Y; Hasegawa, Y | 1 |
| Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L | 1 |
| Hojo, M; Izumi, S; Kamimura, M; Kobayashi, K; Kudo, K; Naka, G; Takeda, Y; Tsuduki, E | 1 |
| Dimou, E; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Xynotroulas, JP | 1 |
| Kanbe, M; Osada, M | 1 |
| Kandabashi, K; Sasaki, T | 1 |
| Ballas, MS; Dennis, PA | 1 |
| Hagiwara, T; Kamataki, T; Kumazawa, E; Nagai, E; Onose, S; Takasuna, K; Watanabe, K; Yoshida, S | 1 |
| Billups, C; Crews, KR; Daw, NC; Dome, JS; Furman, WL; Gajjar, AJ; Houghton, PJ; Panetta, JC; Patrick, CC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Wu, J | 1 |
| Bisonni, R; Leon, A; Lippe, P; Lombardo, M; Marcucci, F; Massacesi, C; Mattioli, R; Pilone, A; Rocchi, MB; Terrazzino, S | 1 |
| Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E | 1 |
| Azrak, RG; Badmaev, V; Creaven, PJ; Fakih, MG; Lawrence, D; Pendyala, L; Prey, JD; Reid, ME; Rustum, YM; Smith, PF | 1 |
| Biasco, G; Brandi, G; Bridonneau, C; Dabard, J; De Vivo, A; Di Battista, M; Morselli Labate, AM; Pantaleo, MA; Pisi, AM; Raibaud, P | 1 |
| Kawahara, M | 1 |
| Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H | 1 |
| Kalofonos, HP; Karabelis, A; Kosmas, C; Koutras, A; Makatsoris, T; Mylonakis, N; Stathopoulos, GP; Syrigos, K; Tsakonas, G; Tsavaris, N | 1 |
| Chamberlain, MC; Groshen, S; Tsao-Wei, DD | 1 |
| Brunet Vidal, J; Cabezas Montero, I; Gumà Padró, J; Llobera Serentill, M; Manzano Alemany, H; Salud Salvia, A; Servitja Tormo, S; Sopena Bert, E; Valentí Moreno, V | 1 |
| Allegrini, G; Amatori, F; Bocci, G; Cerri, E; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Marcucci, L; Masi, G | 1 |
| Bian, JS; Boelsterli, UA; Chan, E; Chan, SY; Chen, YZ; Duan, W; Ho, PC; Hu, ZP; Huang, M; Ng, KY; Yang, XX; Zhou, SF | 1 |
| Arimori, K; Hidaka, M; Ikenoue, T; Iwakiri, T; Nagai, K; Nishida, K; Ogikubo, T; Okumura, M; Setoguchi, N; Yamasaki, K | 1 |
| Cisar, LA; Compton, LD; Duncan, BA; Elfring, GL; Goel, R; Goldberg, RM; Gruia, G; Hammond, LA; Kuhn, JG; McGovren, JP; Miller, LL; Pirotta, N; Rothenberg, ML; Schaaf, LJ; Sharma, A; Tipping, SJ; Yin, D | 1 |
| Cuzzocrea, S; Dorio, AS; Forini, O; Graziani, G; Lapidus, R; Leonetti, C; Mazzon, E; Muzi, A; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J | 1 |
| Aranda, E; Cervantes, A; Dotor, E; Gallén, M; García, JL; Navarro, M; Rivera, F; Sánchez-Rovira, P; Vega-Villegas, ME | 1 |
| Bian, JS; Chan, E; Duan, W; Hu, ZP; Huang, M; Li, X; Sheu, FS; Wang, JC; Xu, AL; Yang, XX; Zhang, Q; Zhou, SF; Zhu, YZ | 1 |
| Asaka, M; Komatsu, Y; Miyagishima, T; Yuki, S | 1 |
| Creemers, GJ; de Bruijn, P; de Jong, FA; de Jonge, MJ; Eskens, FA; Janssen, JT; Kehrer, DF; Mathijssen, RH; Planting, AS; Ruit, JB; Sparreboom, A; van der Gaast, A; van Schaik, RH; Verweij, J | 1 |
| Kessler, FK; Miles, KK; Nielsen, JN; Ritter, JK; Smith, PC; Tallman, MN; Tian, X | 1 |
| Boelsterli, UA; Chan, E; Chan, SY; Duan, W; Ee, PL; Hu, ZP; Huang, M; Koh, HL; Sheu, FS; Wang, JC; Xu, AL; Yang, XX; Zhang, Q; Zhou, SF; Zhu, YZ | 1 |
| Hahn, KK; Kolesar, JM; Wolff, JJ | 1 |
| Higa, GM | 1 |
| Ando, M; Eguchi, K; Fukuoka, M; Ichinose, Y; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Saito, H; Tada, T; Takada, M; Takada, Y; Tamura, K | 1 |
| de Jong, FA; Friberg, LE; Kroetz, DL; Marsh, S; Mathijssen, RH; McLeod, HL; Scott-Horton, TJ; Sparreboom, A; Verweij, J | 1 |
| Bowen, JM; Burns, J; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM; Yeoh, AS | 1 |
| Guan, ZZ | 1 |
| Birdsall, TC | 1 |
| Dranitsaris, G; Shah, A; Spirovski, B; Vincent, M | 1 |
| Cusimano, L; Li, M; Saif, MW; Sellers, S; Wang, H; Wang, W; Zhang, R | 1 |
| Kuboki, Y; Mizunuma, N | 1 |
| Chu, DT; Han, FC; Liu, DQ; Xiu, QY; Zhang, XR; Zhu, YZ | 1 |
| Harita, S; Hotta, K; Kiura, K; Kuyama, S; Okimoto, N; Segawa, Y; Shinkai, T; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Alvarez, E; Bowen, JM; Burns, J; Gibson, RJ; Keefe, DM; Logan, RM; Stringer, AM; Yeoh, AS | 1 |
| Han, JY; Kim, HT; Lee, DH; Lee, JE; Lee, JS; Lee, SY; Lim, HS; Park, YH; Shin, ES; Yoo, YK | 1 |
| Fujiwara, Y; Fukui, T; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Simmyo, Y; Tamura, T; Yamada, K; Yamamoto, N | 1 |
| Kado, S; Kaneda, N; Kato, I; Kurita, A; Matsumoto, T; Onoue, M; Uchida, K; Yokokura, T | 1 |
| Albritton, K; Crews, KR; Furman, WL; McNall-Knapp, RY; Pappo, AS; Rodriguez-Galindo, C; Stewart, CF; Wagner, LM | 1 |
| Benson, A; Wisinski, K | 1 |
| Brito, GA; Carvalho, SB; Cunha, FQ; Melo, ML; Ribeiro, RA; Silva, JV; Soares, PM; Soares, RC; Souza, MH; Vale, ML | 1 |
| Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ | 1 |
| Lagarde, C; Lebrun-Ly, V; Peyronnet, P; Saint-Marcoux, F; Tubiana-Mathieu, N; Vénat-Bouvet, L | 1 |
| Arena, MG; Di Lauro, L; Foggi, P; Lopez, M; Nunziata, C; Sperduti, I | 1 |
| Amado, RG; Berlin, J; Hecht, JR; Malik, I; Meropol, NJ; Navale, L; Patnaik, A; Tchekmedyian, S; Venook, A | 1 |
| Fakih, MG; Ross, ME; Starostik, P | 1 |
| He, YJ; Jiang, WQ; Li, YH; Luo, HY; Shi, YX; Wang, F; Xu, RH; Zhang, L | 1 |
| Bowen, JM; Gibson, RJ; Keefe, DM; Logan, RM; Sonis, ST; Stringer, AM | 1 |
| Alvarez, E; Bowen, JM; Finnie, J; Gibson, RJ; Keefe, DM | 1 |
| Bai, ZG; Jiang, L; Liu, YL; Ma, B; Mi, DH; Tan, JY; Tian, JH; Yang, KH | 1 |
| Fischbach, W; Flieger, D; Hainke, S; Keller, R; Klassert, C; Kleinschmidt, R | 1 |
| Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ | 1 |
| Félix, GM; Luis, JV; Sergio, GC | 1 |
| Boige, V; Cohen, M; Delbaldo, C; Faivre, S; Namouni, F; Pautier, P; Peck, R; Raymond, E; Soria, JC | 1 |
| Fujitani, K; Furukawa, H; Goto, M; Hirao, M; Imano, M; Ishihara, R; Narahara, H; Taguchi, T; Takiuchi, H; Tsujinaka, T; Tsukuma, H; Uedo, N | 1 |
| Carcereny, E; Casado, E; Fernández-Llamazares, J; Font, A; Gallego, R; Guix, M; Manzano, JL; Maurel, J; Ramirez, JL; Rosell, R; Salazar, R; Tabernero, J; Taron, M | 1 |
| Baracos, VE; Dieleman, LA; Field, CJ; Murray, D; Sawyer, MB; Xue, H | 1 |
| Biason, P; Masier, S; Toffoli, G | 1 |
| Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS | 1 |
| Bonneterre, J | 1 |
| Hagiwara, T; Hirohashi, M; Kakihata, K; Kasai, Y; Kitano, Y; Kobayashi, R; Mori, K; Nagai, E; Nomura, M; Takasuna, K | 1 |
| Ikuno, N; Oka, M; Soda, H; Watanabe, M | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Takada, M; Tsukada, H; Yana, T | 1 |
| Hirohashi, M; Kakihata, K; Kasai, Y; Kitano, Y; Mori, K; Nomura, M; Takasuna, K | 1 |
| Abigerges, D; Armand, JP; de Costa, L; Gonçalves, E | 1 |
| Eguchi, K; Hakusui, H; Miya, T; Mizuno, S; Morita, M; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Negoro, S; Takifuji, N; Yoshikawa, A | 1 |
| Catimel, G; Chabot, GG; Clavel, M; Cote, C; Dumortier, A; Engel, C; Gouyette, A; Guastalla, JP; Mahjoubi, M; Mathieu-Boué, A | 1 |
| Abigerges, D; Armand, JP; Chabot, GG; Gandia, D; Gouyette, A; Hérait, P | 1 |
| Kamataki, T; Sakata, Y; Suzuki, H | 1 |
| Gupta, E; Lestingi, TM; Mick, R; Ramirez, J; Ratain, MJ; Vokes, EE | 1 |
| Bugat, R; Chabot, GG; Culine, S; de Forni, M; Extra, JM; Gouyette, A; Madelaine, I; Marty, ME; Mathieu-Boué, A | 1 |
| Akahane, K; Hakusui, H; Hirota, Y; Kawato, Y; Kuga, H; Sato, K; Sekiguchi, M; Suzuki, W; Tsutomi, Y | 1 |
| Abigerges, D; Armand, JP; Chabot, GG; Cote, C; Da Costa, L; Fadel, E; Gandia, D; Hérait, P | 1 |
| Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nishio, M; Ohe, Y; Oshita, F; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Ishida, T; Morimoto, K; Ogawa, M; Ogawa, N; Taguchi, T; Tominaga, T | 1 |
| Masaoka, T; Ohashi, Y; Ohno, R; Okada, K; Ota, K; Shirakawa, S; Taguchi, T | 1 |
| Chen, TL; Donehower, RC; Ettinger, DS; Grochow, LB; Lubejko, BG; Rock, MK; Rowinsky, EK; Sartorius, SE | 1 |
| Ariyoshi, Y; Furue, H; Kimura, I; Masaoka, T; Ogawa, M; Oguro, M; Ohno, R; Saito, H; Sakai, Y; Yoshida, Y | 1 |
| Araki, E; Hoshi, A; Iigo, M; Ishikawa, M; Itabashi, M; Koide, T | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Nitta, T; Takifuji, N; Tamanoi, M | 1 |
| Chou, TC; Conti, JA; Gonzalez, C; Huang, Y; Kemeny, NE; Pulliam, S; Saltz, LB; Sun, M; Tong, WP | 1 |
| Burris, HA; Eckardt, JR; Eckhardt, SG; Elfring, GL; Hilsenbeck, SG; Kuhn, JG; Nelson, J; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Smith, LS; Thurman, AM; Von Hoff, DD; Weiss, GR | 1 |
| Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K | 1 |
| Gupta, E; Mick, R; Ratain, MJ; Vokes, EE | 1 |
| Hagiwara, T; Hirohashi, M; Kamataki, T; Kato, M; Nagai, E; Nomura, M; Takasuna, K; Yokoi, T | 2 |
| Guffroy, M; Hodge, T | 1 |
| Berkery, R; Dietz, A; Eng, M; Kanowitz, J; Kelsen, DP; Kemeny, NE; Locker, P; Saltz, LB; Schaaf, L; Spriggs, D; Staton, BA; Steger, C | 1 |
| Bleiberg, H; Cvitkovic, E | 1 |
| Adenis, A; Becouarn, Y; Bonneterre, J; Brunet, P; Bugat, R; Burki, F; Conroy, T; Culine, S; Douillard, JY; Extra, JM; Ganem, G; Herait, P; Mahjoubi, M; Marty, M; Merrouche, Y; Mousseau, M; Namer, M; Negrier, S; Rougier, P; Seitz, JF; Suc, E; Ychou, M | 1 |
| Ariyoshi, Y; Hotta, T; Kobayashi, T; Ogura, M; Ohashi, Y; Ohnishi, K; Ohno, R; Saito, H; Shirakawa, S; Takeyama, K; Tobinai, K | 1 |
| Mori, K; Ohnishi, T; Tominaga, K; Yokoyama, K | 1 |
| Boku, N; Fujii, T; Fukuda, H; Kondo, H; Muro, K; Oda, Y; Ohtsu, A; Oka, M; Ono, H; Saito, D; Shimada, Y; Shirao, K; Watanabe, Y; Yamao, T; Yokoyama, T; Yoshida, S | 1 |
| Abigerges, D; Armand, JP; Bugat, R; Catimel, G; Extra, JM; Hérait, P; Mahjoubi, M; Marty, M; Merrouche, Y; Suc, E | 1 |
| Bailey, H; Durivage, HJ; Gelder, M; Irvin, WP; Potkul, RK; Price, FV; Rosenbluth, R | 1 |
| Hayakawa, T; Kamataki, T; Kase, Y; Togashi, Y | 1 |
| Aburada, M; Hayakawa, T; Kamataki, T; Kase, Y; Komatsu, Y | 1 |
| Hibino, S; Hino, M; Kabe, J; Kamimura, M; Kobayashi, K; Kudo, K; Kudoh, S; Shibuya, M; Shinbara, A; Takeda, Y | 1 |
| Rowinsky, EK; Siu, LL | 1 |
| Hirose, T; Machida, S; Mori, K; Tominaga, K | 1 |
| Black, JD; Cao, S; Rustum, YM; Troutt, AB | 1 |
| Bastian, G; Bonnay, M; Cote, C; Cvitkovic, E; Hagipantelli, R; Herait, P; Mahjoubi, M; Mignard, D; Misset, JL; Saliba, F; Vassal, G | 1 |
| Erlichman, C; Goldberg, RM | 1 |
| Hecht, JR | 1 |
| Benson, AB; Catalano, R; Engelking, C; Field, M; Kornblau, SM; Mitchell, E; Rubin, J; Trotta, P; Vokes, E; Wadler, S | 1 |
| Abe, S; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Saijo, N; Suzuki, S; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Fujikawa, R; Fukushima, J; Goya, T; Koshiishi, Y; Miya, T; Nogami, H | 1 |
| Cersosimo, RJ | 1 |
| Armand, JP; Boige, V; Raymond, E | 1 |
| Armand, JP; Couteau, C | 1 |
| Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H | 1 |
| Cox, JV; DeVore, RF; Elfring, GL; Geyer, CE; Hainsworth, JD; Macdonald, JS; Miller, LL; Mohrland, JS; Pazdur, R; Rivkin, SE; Rothenberg, ML; Sandbach, J; Von Hoff, DD; Wolf, DL | 1 |
| Amaya, N; Tsutani, H; Ueda, T; Yamauchi, T; Yoshida, A; Yoshio, N | 1 |
| Candalh, E; Kramar, A; Lebecq, A | 1 |
| Chauvergne, J; Chevallier, B; Dieras, V; Fargeot, P; Fumoleau, P; Krakowski, Y; Lentz, MA; Lhommé, C; Matthieu-Boué, A; Mignard, D; Misset, JL; Rebattu, P; Roche, H; Van Glabbeke, M; Vennin, P | 1 |
| Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M | 1 |
| Droege, CM; Hausamen, TU; Lenfers, BH; Loeffler, TM | 1 |
| Al-Zoubi, A; Boucher, J; Savarese, D | 1 |
| Furman, WL; Hanna, SK; Houghton, PJ; Ma, MK; Radomski, KM; Santana, VM; Smith, AK; Stewart, CF; Zamboni, WC | 1 |
| Adenis, A; Burki, F; Douillard, JY; Dufour, P; Marty, M; Mignard, D; Mousseau, M; Rougier, P; Wendling, JL; Ychou, M | 1 |
| Jelic, S; Nikolic-Tomasevic, Z; Popov, I; Radosavljevic, D | 1 |
| Awad, L; Bleiberg, H; Bugat, R; Culine, S; Droz, JP; Freyer, G; Herait, P; Marty, M; Mignard, D; Rougier, P; Trillet-Lenoir, V | 1 |
| Broadwater, R; Govindarajan, R; Hauer-Jensen, M; Heaton, KM; Lang, NP; Zeitlin, A | 1 |
| Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB | 1 |
| Mayer, RJ | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kourousis, CH; Malliotakis, P; Mavroudis, D; Sarra, E; Souglakos, J | 1 |
| Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A | 1 |
| Kelsen, DP; Kemeny, NE; O'Reilly, EM; Raeburn, L; Saltz, LB; Sanz-Altamira, PM; Schwartz, GK; Steger, CM; Stuart, KE | 1 |
| Elfring, GL; Hanover, CK; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Pirotta, N; Sandler, AB; Socinski, MA | 1 |
| Pestalozzi, BC | 1 |
| de Bruijn, P; de Jonge, MJ; Kehrer, DF; Nierop, CA; Ruijgrok, EJ; Sparreboom, A; van de Schraaf, J; Verweij, J | 1 |
| Barbounis, V; Demiri, M; Efremidis, AP; Koumakis, G; Vassilomanolakis, M | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Erlichman, C; Goldberg, RM; Kaufmann, SH; Okuno, SH; Pitot, HC; Rubin, J; Sloan, J | 1 |
| Arimori, K; Kikuchi, M; Kumamoto, A; Kumazawa, E; Kuroki, N; Nakano, M; Tanoue, N; Tohgo, A | 1 |
| Ajani, JA; Lozano, R; Pro, B | 1 |
| Algazy, K; Giantonio, B; Haller, DG; Hardy, C; Kluijtmans, LA; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Whitehead, AS | 1 |
| Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M | 1 |
| Ratain, MJ | 1 |
| Arimori, K; Bouscarel, B; Ceryak, S; Ha, L; Ikegami, T; Kobayashi, K; Latham, P; Matsuzaki, Y | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Ikeda, T; Minami, H; Saka, H; Sakai, S; Sato, M; Sekido, Y; Shimokata, K; Watanabe, A; Yamamoto, M | 1 |
| Chin, K; Goto, M; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yamao, T | 1 |
| Aiba, K; Fujiwara, K; Horikoshi, N; Ito, Y; Mizunuma, N; Omachi, K; Saotome, T; Sugiyama, K; Takahashi, S | 1 |
| Ajani, JA; Baker, J; Charnsangavej, C; Feig, BW; Ho, L; Mansfield, PF; Pisters, PW | 1 |
| Calleja, E; Cosetti, M; Gerald, W; Gorlick, R; Healey, JH; Huvos, AG; LaQuaglia, M; Meyers, PA; Trippett, T; Wexler, LH | 1 |
| Asami, K; Kaneko, M; Kishimoto, T; Matsunaga, T; Mimaya, J; Mugishima, H; Sawada, T; Suita, S; Tsuchida, Y; Yagi, K | 1 |
| Chamberlain, MC | 1 |
| Delioukina, ML; Hecht, JR; Parson, M; Prager, D; Rosen, LS; Rosen, P | 1 |
| Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N | 1 |
| Tchekmedyian, NS | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Ariyoshi, Y; Fukuoka, M; Hasegawa, K; Kuriyama, T; Masuda, N; Motomiya, M; Negoro, S; Niitani, H; Nishiwaki, Y; Suzuki, A | 1 |
| Eguchi, K; Karato, A; Kojima, A; Kunikane, H; Ohe, Y; Ohmatsu, H; Okamoto, H; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
54 review(s) available for irinotecan and Diarrhea
| Article | Year |
|---|---|
Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.
Topics: Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Precision Medicine; Topoisomerase I Inhibitors | 2021 |
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Diarrhea; Humans; Immunoconjugates; Irinotecan; Neutropenia; Urinary Bladder Neoplasms | 2022 |
Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.
Topics: Antineoplastic Agents, Phytogenic; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Neutropenia; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2022 |
Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis.
Topics: Colorectal Neoplasms; Diarrhea; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Genetic; Risk Assessment; Risk Factors; Topoisomerase I Inhibitors; Treatment Outcome | 2020 |
Human gut bacterial β-glucuronidase inhibition: An emerging approach to manage medication therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Gastrointestinal Microbiome; Gastrointestinal Tract; Glucuronidase; Glycoproteins; Humans; Irinotecan; Precision Medicine; Protein Structure, Secondary; Topoisomerase I Inhibitors | 2021 |
Sacituzumab govitecan: an antibody-drug conjugate.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Humans; Immunoconjugates; Irinotecan; Neoplasms; Neutropenia; Urologic Neoplasms | 2017 |
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting | 2017 |
UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.
Topics: Antineoplastic Agents; Diarrhea; Female; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide | 2018 |
Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposide; Hematologic Diseases; Humans; Incidence; Irinotecan; Lung Neoplasms; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vomiting | 2018 |
Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Bacterial Proteins; Biomarkers; Diarrhea; Gastrointestinal Microbiome; Glucuronidase; Humans; Intestines; Irinotecan; Severity of Illness Index | 2019 |
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.
Topics: Aged; Alleles; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Female; Genetic Association Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Single Nucleotide; Risk Factors; White People | 2014 |
Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Hospitalization; Humans; Irinotecan; Molecular Targeted Therapy; Multidrug Resistance-Associated Protein 2; Severity of Illness Index; Topoisomerase I Inhibitors | 2013 |
Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Neutropenia; Pharmacogenetics | 2012 |
[Relationship between UGT1A and irinotecan-related toxicity].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Single Nucleotide | 2013 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplasms; Diarrhea; Disease Models, Animal; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Inflammation; Intestinal Mucosa; Irinotecan; Mucositis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin | 2014 |
A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiotoxicity; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Liver; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2014 |
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Nausea; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic | 2016 |
Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genetic Predisposition to Disease; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Meta-Analysis as Topic; Neutropenia; Odds Ratio; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Predictive Value of Tests; Reproducibility of Results; Risk Assessment; Risk Factors; Systematic Reviews as Topic; Treatment Outcome | 2017 |
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis; Randomized Controlled Trials as Topic; Risk Factors | 2008 |
Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Pharmacology, Clinical; Risk Assessment; Sex Distribution; Survival Analysis; Treatment Outcome | 2008 |
Irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; ErbB Receptors; Genetic Predisposition to Disease; Humans; Irinotecan; Neutropenia | 2007 |
Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Irinotecan; Metabolic Networks and Pathways; Models, Biological; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Risk Assessment | 2008 |
Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic | 2010 |
Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Prodrugs; Radiotherapy, Adjuvant | 2010 |
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Logistic Models; Middle Aged; Multivariate Analysis; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Stomatitis; Survival Analysis; Treatment Outcome | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Research Design; Treatment Outcome | 2011 |
Diarrhea.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colitis; Colon; Colonoscopy; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Enterocolitis, Pseudomembranous; Gastrointestinal Motility; Humans; Irinotecan; Muscle Contraction; Sodium-Potassium-Exchanging ATPase; Steatorrhea | 2011 |
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Biomarkers, Pharmacological; Camptothecin; Diarrhea; Genetic Association Studies; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Neoplasms; Neutropenia | 2012 |
Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effects.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Treatment Outcome | 2002 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Risk Factors; Stomatitis; Survival; Treatment Outcome | 2002 |
Lessons learned from the irinotecan metabolic pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Biotransformation; Camptothecin; Carboxylic Ester Hydrolases; Carrier Proteins; Cytochrome P-450 CYP3A; Diarrhea; Glucuronides; Humans; Irinotecan; Oxidoreductases, N-Demethylating | 2003 |
[Chemotherapy-induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Camptothecin; Diarrhea; Humans; Irinotecan; Neoplasms; Treatment Outcome | 2003 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Nausea; Stomatitis; Thrombocytopenia; Vomiting | 2003 |
Overview of chemotherapy-induced diarrhea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinotecan; Neoplasms; Nurse-Patient Relations; Nursing Assessment; Nursing Methodology Research; Octreotide; Oncology Nursing; Quality of Life | 2003 |
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Enzyme Inhibitors; Glucuronidase; Glucuronides; Glucuronosyltransferase; Humans; Intestines; Irinotecan; Loperamide; Topoisomerase I Inhibitors | 2004 |
Novel agents that potentially inhibit irinotecan-induced diarrhea.
Topics: Animals; Antidiarrheals; Camptothecin; Diarrhea; Enzyme Inhibitors; Humans; Irinotecan | 2005 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cause of Death; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Costs; Drug Hypersensitivity; Drug Industry; Female; Fluorouracil; Humans; Irinotecan; Male; Medical Assistance; Nausea; Neoplasm Staging; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Patient Education as Topic; Treatment Outcome; United States; Vomiting | 2005 |
Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Diarrhea; Dose-Response Relationship, Drug; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Patient Compliance; Quality of Life | 2006 |
Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Prospective Studies; Sodium Bicarbonate | 2006 |
Pharmacogenetics and irinotecan therapy.
Topics: Antineoplastic Agents; Bilirubin; Biomarkers; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Drug Labeling; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Practice Guidelines as Topic; Risk Assessment | 2006 |
[Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Survival Analysis | 2006 |
Reducing irinotecan-associated diarrhea in children.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cephalosporins; Child; Diarrhea; Genetic Predisposition to Disease; Humans; Irinotecan | 2008 |
Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: a metaanalysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Randomized Controlled Trials as Topic; Vomiting | 2007 |
UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Gene Frequency; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Neoplasm Metastasis; Neoplasms; Neutropenia; Polymorphism, Genetic | 2008 |
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting | 1995 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Middle Aged; Neutropenia | 1996 |
Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; North America | 1998 |
Gastrointestinal toxicity or irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cholinergic Agents; Diarrhea; Gastrointestinal Diseases; Humans; Irinotecan | 1998 |
Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Gastrointestinal Agents; Humans; Irinotecan; Octreotide; Practice Guidelines as Topic | 1998 |
Irinotecan: a new antineoplastic agent for the management of colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia | 1998 |
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Hepatic Artery; Humans; Inactivation, Metabolic; Injections, Intra-Arterial; Injections, Intravenous; Irinotecan; Neoplasm Proteins; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Diarrhea; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neuroectodermal Tumors, Primitive; New York City; Osteosarcoma; Retrospective Studies; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
203 trial(s) available for irinotecan and Diarrhea
| Article | Year |
|---|---|
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liposomes; Logistic Models; Male; Metabolic Clearance Rate; Models, Biological; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms | 2021 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms | 2023 |
A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Humans; Irinotecan; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors | 2023 |
Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy.
Topics: Abdominal Pain; Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Data Analysis; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Nausea; Organs at Risk; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Radiation Dosage; Radiosurgery; Time Factors | 2020 |
The Impact of Chemotherapy Completion on the Efficacy of Irinotecan in the Preoperative Chemoradiotherapy of Locally Advanced Rectal Cancer: An Expanded Analysis of the CinClare Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Nomograms; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Risk Factors; Treatment Outcome | 2020 |
Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Diarrhea; Double-Blind Method; Drugs, Chinese Herbal; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Multicenter Studies as Topic; Pre-Exposure Prophylaxis; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Small Cell Lung Carcinoma; Treatment Outcome; Young Adult | 2020 |
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Oxaliplatin; Peripheral Nervous System Diseases; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2020 |
Effects of Protein and Calorie Restriction on the Metabolism and Toxicity Profile of Irinotecan in Cancer Patients.
Topics: Aged; Caloric Restriction; Diarrhea; Diet, Protein-Restricted; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia | 2021 |
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Topics: Administration, Metronomic; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Diarrhea; Drug Delivery Systems; Female; Glioblastoma; Humans; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Nanostructures; Neutropenia; Temozolomide | 2021 |
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Dietary Supplements; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Pilot Projects; Prospective Studies; Protective Agents; Silymarin; Treatment Outcome; Young Adult | 2021 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arylamine N-Acetyltransferase; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Catecholamine Plasma Membrane Transport Proteins; Cetuximab; Colorectal Neoplasms; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Glucuronosyltransferase; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome; Vitamin K Epoxide Reductases | 2017 |
A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer.
Topics: Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hyponatremia; Irinotecan; Lung Neoplasms; Male; Middle Aged; Response Evaluation Criteria in Solid Tumors; Retreatment; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Neoplasm Metastasis; Oxonic Acid; Survival Rate; Tegafur | 2018 |
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Body Surface Area; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Glucuronosyltransferase; Humans; Incidence; Irinotecan; Leucovorin; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neutropenia; Neutrophils; Sex Factors; Treatment Outcome; Young Adult | 2018 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Treatment Outcome; Vomiting; Young Adult | 2017 |
A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma; Diarrhea; Disease-Free Survival; DNA-Binding Proteins; Endometrial Neoplasms; Endonucleases; Female; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Survival Rate; Thrombocytopenia; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2018 |
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Adhesion Molecules; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Immunoconjugates; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Progression-Free Survival; Survival Rate; Triple Negative Breast Neoplasms | 2019 |
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Colorectal Neoplasms; Diarrhea; Drug Eruptions; Epiregulin; ErbB Receptors; Female; GTP Phosphohydrolases; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Magnesium; Male; Membrane Proteins; Middle Aged; Panitumumab; Peritoneal Neoplasms; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Salvage Therapy; Survival Rate; Treatment Outcome; Water-Electrolyte Imbalance | 2019 |
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2013 |
A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Camptothecin; Colorectal Neoplasms; Cyclosporine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Odds Ratio; Time Factors; Treatment Outcome; United Kingdom | 2013 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2014 |
A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Protective Agents; Treatment Outcome | 2014 |
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Delayed-Action Preparations; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Loperamide; Male; Middle Aged; Octreotide; Quality of Life; Severity of Illness Index; Young Adult | 2014 |
Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cetuximab; Diarrhea; Disease-Free Survival; Docetaxel; Enoxaparin; Female; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Response Evaluation Criteria in Solid Tumors; Survival Rate; Taxoids; Thromboembolism | 2016 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2014 |
A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Gastrins; Humans; Infusions, Intravenous; Injections, Intramuscular; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Vomiting | 2014 |
A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Aluminum Silicates; Antineoplastic Agents, Phytogenic; Camptothecin; Clay; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Placebos; Treatment Outcome; Young Adult | 2015 |
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Treatment Outcome; Young Adult | 2014 |
Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Diarrhea; Female; Follow-Up Studies; Humans; Intestine, Small; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rectal Neoplasms | 2015 |
Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study.
Topics: Aged; Aged, 80 and over; Camptothecin; Diarrhea; Double-Blind Method; Female; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Probiotics | 2015 |
Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Diarrhea; Feasibility Studies; Febrile Neutropenia; Female; Humans; Hypokalemia; Hyponatremia; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Small Cell Lung Carcinoma; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2015 |
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Hedgehog Proteins; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome; Veratrum Alkaloids; Vomiting | 2016 |
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Topics: Adenocarcinoma; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Febrile Neutropenia; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Salvage Therapy; Sulfonamides; Treatment Outcome | 2015 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Combinations; Fatigue; Female; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
A multicenter phase I study of preoperative chemoradiotherapy with S-1 and irinotecan for locally advanced lower rectal cancer (SAMRAI-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Radiotherapy Planning, Computer-Assisted; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2016 |
Population-based phase I trial of irinotecan and epirubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Topoisomerase I Inhibitors | 2008 |
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Spain; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Nausea; Proctitis; Rectal Neoplasms; Remission Induction; Vomiting | 2009 |
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Digestive System Neoplasms; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Time Factors; Treatment Outcome | 2009 |
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Diarrhea; Etoposide; Female; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Factors; Small Cell Lung Carcinoma | 2009 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Vomiting | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Colitis; Dacarbazine; Diarrhea; Female; Humans; Irinotecan; Male; Neutropenia; Pneumonia; Recurrence; Remission Induction; Retrospective Studies; Sarcoma, Ewing; Temozolomide; Thrombocytopenia; Young Adult | 2009 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Deoxycytidine; Diarrhea; Fecal Incontinence; Female; Fluorouracil; Gangrene; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Proctitis; Pyrazoles; Radiation Injuries; Radiation-Sensitizing Agents; Rectal Neoplasms; Sulfonamides | 2010 |
Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fever; Follow-Up Studies; Gastrectomy; Humans; Infusions, Parenteral; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Peritoneal Dialysis, Continuous Ambulatory; Peritoneal Neoplasms; Stomach Neoplasms | 2011 |
Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Carriers; Female; Humans; Hyaluronic Acid; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Risk Factors; Survival; Treatment Outcome | 2011 |
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Eruptions; Female; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Treatment Outcome | 2010 |
A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Japan; Leukopenia; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Oxonic Acid; Rectal Neoplasms; Tegafur | 2011 |
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2010 |
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Oxonic Acid; Patient Selection; Salvage Therapy; Serum Albumin; Stomach Neoplasms; Survival; Tegafur; Treatment Outcome | 2011 |
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
Topics: Adolescent; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cefpodoxime; Ceftizoxime; Child; Child, Preschool; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Topoisomerase I Inhibitors; Young Adult | 2012 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuritis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Stomach Neoplasms; Young Adult | 2011 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Rate; Thrombocytopenia | 2012 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Research Design; Treatment Outcome | 2011 |
Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia | 2012 |
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Catheterization; Diarrhea; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2011 |
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Survival Rate; Young Adult | 2011 |
Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC).
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cetuximab; Colonic Neoplasms; Diarrhea; ErbB Receptors; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Rectal Neoplasms; Skin Diseases; Treatment Outcome | 2012 |
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypertension; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Severity of Illness Index; Tegafur; Treatment Outcome | 2012 |
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thymidine Phosphorylase; Treatment Outcome | 2012 |
Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Diarrhea; Female; Hepatectomy; Hepatoblastoma; Humans; Infant; Irinotecan; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Salvage Therapy; Treatment Outcome | 2012 |
A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Carboplatin; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sepsis; Small Cell Lung Carcinoma; Thrombosis | 2012 |
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Severity of Illness Index; Small Cell Lung Carcinoma; Thrombocytopenia; Treatment Outcome | 2012 |
[A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Thrombocytopenia | 2012 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Quality of Life; Time Factors; Treatment Outcome; Venous Thrombosis | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Vomiting | 2002 |
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Vomiting | 2002 |
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thiophenes | 2002 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Neutropenia | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Rate; Treatment Outcome; Vomiting | 2002 |
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Prodrugs; Rectal Neoplasms; Remission Induction; Safety; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Mouth Mucosa; Neoplasm Metastasis; Stomatitis; Treatment Outcome | 2002 |
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia | 2003 |
Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drugs, Chinese Herbal; Female; Humans; Irinotecan; Lung Neoplasms; Male; Medicine, Kampo; Middle Aged; Treatment Outcome | 2003 |
Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Recurrence; Salvage Therapy; Survival Analysis; Topoisomerase I Inhibitors; Treatment Outcome | 2003 |
Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Linear Models; Lung Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Vindesine; Vomiting, Anticipatory | 2003 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Spain; Treatment Outcome; Vomiting | 2003 |
Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Survival Analysis; Taxoids; Vomiting | 2004 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Tegafur; Treatment Outcome; Uracil | 2004 |
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis | 2003 |
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Quinolones | 2004 |
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Glucuronides; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Patient Selection; Quinazolines; Thiophenes; Vomiting | 2004 |
Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids | 2004 |
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Humans; Infusion Pumps; Irinotecan; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2004 |
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting | 2004 |
Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Shock, Septic; Stomatitis; Survival Rate | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Remission Induction; Treatment Outcome | 2004 |
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Pharmacogenetics; Polymorphism, Genetic; Promoter Regions, Genetic; Survival Analysis; TATA Box | 2004 |
Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients.
Topics: Adsorption; Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Carbon; Defecation; Diarrhea; Female; Humans; Irinotecan; Male; Microspheres; Middle Aged; Neoplasms; Oxides; Time Factors; Treatment Outcome | 2004 |
The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Atropine; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Irinotecan; Male; Middle Aged; Muscarinic Antagonists; Neoplasm Metastasis | 2004 |
A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Stomatitis; Survival Analysis; Survival Rate | 2004 |
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2004 |
Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Greece; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Patient Selection; Taxoids; Time Factors; Treatment Outcome; Withholding Treatment | 2004 |
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Charcoal; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2004 |
Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutropenia; Quality of Life; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Genetic; Prognosis; Prospective Studies; Treatment Outcome; UDP-Glucuronosyltransferase 1A9 | 2005 |
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Capsules; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; Dietary Fats; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2005 |
Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Transplantation, Heterologous | 2005 |
First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Irinotecan; Male; Middle Aged; Neutropenia; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Vomiting | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome | 2005 |
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusion Pumps; Irinotecan; Leucovorin; Male; Neoplasms; Neutropenia; Pharmacogenetics; Promoter Regions, Genetic; Thymidylate Synthase; Treatment Outcome | 2005 |
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrazoles; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Caco-2 Cells; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Enzyme Induction; Female; Flavonoids; Glucuronates; Glucuronosyltransferase; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pilot Projects | 2006 |
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Budesonide; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Female; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Topoisomerase I Inhibitors; Treatment Outcome | 2005 |
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting | 2005 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Prodrugs; Rectal Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2005 |
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Glutamine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis | 2005 |
Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Time Factors | 2005 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vomiting | 2005 |
A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antacids; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cholagogues and Choleretics; Cisplatin; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Maximum Tolerated Dose; Middle Aged; Sodium Bicarbonate; Survival Analysis; Ursodeoxycholic Acid | 2005 |
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dexamethasone; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2005 |
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Cefixime; Child; Child, Preschool; Chromatography, High Pressure Liquid; Diarrhea; Feces; Female; Glucuronidase; Humans; Irinotecan; Lactones; Male; Neoplasms; Severity of Illness Index | 2006 |
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon-Nitrogen Ligases; Carcinoma; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Promoter Regions, Genetic; Quinazolines; Thiophenes; Thymidylate Synthase; Vomiting | 2006 |
Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Selenomethionine; Treatment Outcome | 2006 |
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Survivors; Tegafur; Treatment Outcome | 2006 |
A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Patient Compliance; Quality of Life; Survival Analysis; Taxoids | 2007 |
Salvage chemotherapy with CPT-11 for recurrent meningioma.
Topics: Aged; Agranulocytosis; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Male; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Treatment Failure | 2006 |
Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Prospective Studies; Sodium Bicarbonate | 2006 |
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Diarrhea; Disorders of Excessive Somnolence; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Thalidomide; Treatment Outcome | 2006 |
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Diseases; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Patient Selection | 2006 |
A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Diarrhea; Drug Administration Schedule; Fecal Incontinence; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Irinotecan; Male; Middle Aged; Pancytopenia; Radiotherapy Dosage; Rectal Neoplasms | 2006 |
[Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capsules; Diarrhea; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Nausea; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Mass Screening; Middle Aged; Neomycin; Placebos; Stomach Neoplasms | 2006 |
Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease-Free Survival; Etoposide; Female; Fever; Humans; Infections; Irinotecan; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy Dosage; Radiotherapy, Adjuvant; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2006 |
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Small Cell; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Female; Gastrointestinal Hemorrhage; Gemcitabine; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms | 2007 |
[Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Survival Rate | 2006 |
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2007 |
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Gene Frequency; Genotype; Haplotypes; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neutropenia; Polymorphism, Genetic; Treatment Outcome | 2007 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2007 |
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease Progression; Docetaxel; Esophagogastric Junction; Female; Fever; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2007 |
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Skin Diseases; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antidiarrheals; Camptothecin; Cholestyramine Resin; Colorectal Neoplasms; Diarrhea; Female; Humans; Irinotecan; Levofloxacin; Male; Middle Aged; Ofloxacin; Time Factors | 2007 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis | 2008 |
Activated charcoal to prevent irinotecan-induced diarrhea in children.
Topics: Adolescent; Antineoplastic Agents; Camptothecin; Charcoal; Child; Child, Preschool; Diarrhea; Female; Humans; Infant; Irinotecan; Male; Neoplasms; Treatment Outcome | 2008 |
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Epothilones; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Paresthesia; Vomiting | 2008 |
Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2007 |
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease Progression; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Single Nucleotide; Stomach Neoplasms; Survival Analysis; Taxoids; Xeroderma Pigmentosum Group D Protein | 2008 |
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Half-Life; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Remission Induction; Thrombocytopenia | 1994 |
A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Japan; Kinetics; Leukopenia; Male; Middle Aged; Neoplasms; Prospective Studies | 1995 |
Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Drug Interactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors | 1995 |
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Alopecia; Camptothecin; Chromatography, High Pressure Liquid; Diarrhea; Drug Administration Schedule; Female; Half-Life; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasms; Prodrugs; Salvage Therapy; Treatment Outcome | 1995 |
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Gastrointestinal Diseases; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Treatment Outcome; Vomiting | 1995 |
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Glucuronates; Humans; Irinotecan | 1994 |
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia | 1994 |
Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Neoplasms | 1994 |
Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Vindesine | 1994 |
[A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged | 1994 |
[Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies].
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Feasibility Studies; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Muscle Cramp; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting | 1994 |
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with hematological malignancies].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Irinotecan; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1993 |
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adenocarcinoma; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Irinotecan; Loperamide; Salvage Therapy; Survival Analysis; Treatment Outcome | 1996 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Topics: Antineoplastic Agents, Phytogenic; Biliary Tract; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasms | 1996 |
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms | 1996 |
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction | 1997 |
Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma. CPT-11/Lymphoma Study Group.
Topics: Abdominal Pain; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Vomiting | 1996 |
A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1997 |
Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Stomach Neoplasms; Thrombocytopenia | 1997 |
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Thrombocytopenia | 1997 |
A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Patient Satisfaction; Pilot Projects; Platinum Compounds; Remission Induction; Safety; Uterine Cervical Neoplasms; Vomiting | 1998 |
Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged | 1998 |
[Kampo medicines for the prevention of irinotecan-induced diarrhea in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Drug Administration Schedule; Drugs, Chinese Herbal; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1998 |
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Prospective Studies; Thiorphan | 1998 |
Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Nausea; Recombinant Proteins; Reproducibility of Results; Vomiting | 1997 |
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Remission Induction | 1999 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Vomiting | 1999 |
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 1999 |
Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Budesonide; Camptothecin; Diarrhea; Female; Fluorouracil; Glucocorticoids; Humans; Irinotecan; Loperamide; Male; Middle Aged; Treatment Failure | 1999 |
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Complex and Mixed; Neoplasms, Connective and Soft Tissue; Neoplasms, Glandular and Epithelial; Neutropenia; Time Factors | 2000 |
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome | 2000 |
Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.
Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Proteins; Camptothecin; Colorectal Neoplasms; Creatinine; Diarrhea; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Patient Selection; Risk Factors; Urea | 2000 |
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Neutropenia; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Factors; Thiorphan | 2000 |
Effect of thalidomide on gastrointestinal toxic effects of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Digestive System; Humans; Irinotecan; Pilot Projects; Thalidomide | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mouth Mucosa; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Quality of Life; Stomatitis; Survival Analysis | 2000 |
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fever; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids | 2000 |
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Infections; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Sensation Disorders; Treatment Outcome | 2000 |
A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Diarrhea; Fatigue; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Prognosis; Treatment Outcome; Vomiting | 2001 |
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel | 2001 |
Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
Topics: Adult; Aged; Antacids; Antineoplastic Agents, Phytogenic; Bone Marrow; Buffers; Camptothecin; Case-Control Studies; Defecation; Diarrhea; Digestive System; Female; Humans; Hydrogen-Ion Concentration; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Middle Aged; Risk Factors; Sodium Bicarbonate; Ursodeoxycholic Acid | 2001 |
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Diarrhea; Humans; Irinotecan; Middle Aged; Neomycin; Neoplasms | 2001 |
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 2001 |
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Genotype; Homocysteine; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasms; Neutropenia; Oxidoreductases Acting on CH-NH Group Donors; Quinazolines; Thiophenes | 2001 |
Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Tegafur; Uracil | 2001 |
Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Treatment Outcome | 2001 |
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Neutropenia; Stomach Neoplasms; Survival Rate; Thrombocytopenia | 2001 |
Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2002 |
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Stomach Neoplasms; Treatment Outcome | 2002 |
Phase I study of irinotecan in pediatric patients with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Camptothecin; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Irinotecan; Japan; Leiomyosarcoma; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Neoplasm Proteins; Neuroblastoma; Neuroectodermal Tumors, Primitive; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Salvage Therapy; Supratentorial Neoplasms; Thrombocytopenia | 2002 |
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Pilot Projects | 2002 |
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Compliance; Quality of Life; Survival Analysis | 2002 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Evaluation; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged | 1992 |
Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Diarrhea; Drug Evaluation; Esophageal Neoplasms; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Middle Aged; Pharyngeal Neoplasms | 1992 |
194 other study(ies) available for irinotecan and Diarrhea
| Article | Year |
|---|---|
Selenium-enriched Bifidobacterium longum DD98 attenuates irinotecan-induced intestinal and hepatic toxicity in vitro and in vivo.
Topics: Animals; Bifidobacterium longum; Cell Line; Chemical and Drug Induced Liver Injury; Cytokines; Diarrhea; Disease Models, Animal; Feces; Gastrointestinal Microbiome; Inflammation Mediators; Intestines; Irinotecan; Liver; Mice, Inbred BALB C; Oxidative Stress; Probiotics; Rats; Selenium; Tight Junction Proteins; Weight Loss | 2021 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; Camptothecin; Diarrhea; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Nausea; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Thrombocytopenia; Vomiting | 2022 |
Development of a physiologically based pharmacokinetic model to predict irinotecan disposition during inflammation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Glucuronosyltransferase; Inflammation; Irinotecan; Mice | 2022 |
Efficacy and Side Effects of Irinotecan Combined with Nedaplatin versus Paclitaxel Combined with Cisplatin in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer and Tumor Marker Analysis: Based on a Retrospective Analysis.
Topics: Abdominal Pain; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Exanthema; Female; Humans; Hyperglycemia; Irinotecan; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms; Vomiting | 2022 |
Evaluation of UGT1A1 and CYP3A Genotyping and Single-Point Irinotecan and Metabolite Concentrations as Predictors of the Occurrence of Adverse Events in Cancer Treatment.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP3A; Diarrhea; Genotype; Humans; Irinotecan; Neoplasms | 2023 |
Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
Topics: Camptothecin; Diarrhea; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia | 2023 |
Evaluation and validation of chemotherapy-specific diarrhoea and histopathology in rats.
Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; Diarrhea; Doxorubicin; Fluorouracil; Idarubicin; Intestinal Mucosa; Irinotecan; Male; Methotrexate; Mucositis; Rats; Rats, Wistar | 2022 |
Vitamin A Ameliorated Irinotecan-Induced Diarrhea in a Piglet Model Involving Enteric Glia Modulation and Immune Cells Infiltration.
Topics: Animals; Diarrhea; Enteric Nervous System; Gliosis; Inflammation; Intestine, Small; Irinotecan; Neuroglia; Swine; Vitamin A | 2022 |
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity.
Topics: Animals; Colonic Neoplasms; Diarrhea; Escherichia coli; Gastrointestinal Microbiome; Glucuronidase; Irinotecan; Mice; Reactive Oxygen Species; RNA, Ribosomal, 16S | 2023 |
Chemotherapy-induced ileitis associated or not with colitis in digestive oncology patients: An AGEO multicentre study.
Topics: Antineoplastic Agents; Colitis; Diarrhea; Humans; Ileitis; Irinotecan; Neoplasms | 2023 |
Green tea extract prevents CPT-11-induced diarrhea by regulating the gut microbiota.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Bacteria; Camptothecin; Diarrhea; Gastrointestinal Microbiome; Glucuronidase; Irinotecan; Rats; Tea | 2023 |
Design, synthesis, and biological evaluation studies of novel carboxylesterase 2 inhibitors for the treatment of irinotecan-induced delayed diarrhea.
Topics: Diarrhea; Enzyme Inhibitors; Humans; Irinotecan; Molecular Docking Simulation; Molecular Dynamics Simulation | 2023 |
Discovery of novel carboxylesterase 2 inhibitors for the treatment of delayed diarrhea and ulcerative colitis.
Topics: Camptothecin; Carboxylesterase; Colitis, Ulcerative; Diarrhea; Humans; Intestines; Irinotecan; Structure-Activity Relationship | 2023 |
Treatment with S-adenosylmethionine ameliorates irinotecan-induced intestinal barrier dysfunction and intestinal microbial disorder in mice.
Topics: Animals; Caco-2 Cells; Diarrhea; Gastrointestinal Diseases; Humans; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Mice; Occludin; S-Adenosylmethionine; Tight Junctions | 2023 |
Insight into the mechanism of Xiao-Chai-Hu-Tang alleviates irinotecan-induced diarrhea based on regulating the gut microbiota and inhibiting Gut β-GUS.
Topics: Animals; Cytokines; Diarrhea; Gastrointestinal Microbiome; Glucuronidase; Irinotecan; Mice; RNA, Ribosomal, 16S | 2023 |
Baicalein, a component of banxia xiexin decoction, alleviates CPT-11-induced gastrointestinal dysfunction by inhibiting ALOX15-mediated ferroptosis.
Topics: Animals; Arachidonate 15-Lipoxygenase; Diarrhea; Ferroptosis; Irinotecan; Rats | 2023 |
Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan's Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea.
Topics: Animals; Biliary Tract; Diarrhea; Drugs, Chinese Herbal; Intestinal Mucosa; Irinotecan; Male; Rats; Rats, Wistar; Tissue Distribution | 2019 |
Ganciclovir reduces irinotecan-induced intestinal toxicity by inhibiting NLRP3 activation.
Topics: Animals; Antiviral Agents; Apoptosis; Biomarkers; Cell Proliferation; Colonic Neoplasms; Diarrhea; Ganciclovir; Gene Expression Regulation; Humans; Inflammation; Intestinal Diseases; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NLR Family, Pyrin Domain-Containing 3 Protein; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Identify old drugs as selective bacterial β-GUS inhibitors by structural-based virtual screening and bio-evaluations.
Topics: Antidiarrheals; Aspartame; Bacteria; Bacterial Proteins; Camptothecin; Clozapine; Diarrhea; Drug Evaluation, Preclinical; Enzyme Inhibitors; Escherichia coli; Gemifloxacin; Glucuronates; Glucuronidase; Humans; Irinotecan; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Protein Conformation; Structure-Activity Relationship | 2020 |
Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; United States | 2020 |
Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Diarrhea; Disease Models, Animal; Glycerol; Heterografts; Humans; Hydrophobic and Hydrophilic Interactions; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2020 |
Isolation and Structural Characterization of Specific Bacterial β-Glucuronidase Inhibitors from Noni (
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Circular Dichroism; Diarrhea; Fruit; Glucuronidase; Glycoproteins; Irinotecan; Magnetic Resonance Spectroscopy; Molecular Structure; Morinda; Plant Extracts; Rats; Spectrometry, Mass, Electrospray Ionization | 2020 |
Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bile; Biliary Tract; Caco-2 Cells; Cell Line, Tumor; Diarrhea; Esterases; Female; Glucuronosyltransferase; Humans; Intestines; Irinotecan; Mice; Tissue Distribution | 2020 |
Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Diarrhea; Disease Progression; Drug Administration Schedule; Humans; Irinotecan; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Salvage Therapy; Sarcoma, Ewing; Temozolomide | 2021 |
Identification of the bioactive components of Banxia Xiexin Decoction that protect against CPT-11-induced intestinal toxicity via UPLC-based spectrum-effect relationship analyses.
Topics: Animals; Chromatography, High Pressure Liquid; Diarrhea; Drugs, Chinese Herbal; Female; Intestinal Diseases; Irinotecan; Mice; Mice, Inbred ICR; Tandem Mass Spectrometry; Topoisomerase I Inhibitors | 2021 |
A multifunctional SN38-conjugated nanosystem for defeating myelosuppression and diarrhea induced by irinotecan in esophageal cancer.
Topics: Animals; Cell Line, Tumor; Diarrhea; Esophageal Neoplasms; Irinotecan; Manganese Compounds; Mice; Nanoparticles; Oxides; Phototherapy; Tumor Microenvironment | 2020 |
Lactobacillus Kefiri LKF01 (Kefibios
Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Diarrhea; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Lactobacillus; Male; Probiotics; Prospective Studies; Treatment Outcome | 2021 |
Entropy-driven binding of gut bacterial β-glucuronidase inhibitors ameliorates irinotecan-induced toxicity.
Topics: Animals; Bacteria; Cell Line; Colon; Diarrhea; Disease Models, Animal; Enzyme Inhibitors; Female; Gastrointestinal Microbiome; Glucuronidase; Humans; Imino Pyranoses; Irinotecan; Mice, Inbred BALB C; Uronic Acids | 2021 |
Mechanisms of Gegen Qinlian Pill to ameliorate irinotecan-induced diarrhea investigated by the combination of serum pharmacochemistry and network pharmacology.
Topics: Animals; Body Weight; Diarrhea; Disease Models, Animal; Drugs, Chinese Herbal; Gastrointestinal Diseases; Gene Expression Regulation; Heme Oxygenase-1; Inflammation; Intestines; Irinotecan; Kelch-Like ECH-Associated Protein 1; Membrane Proteins; Metabolic Networks and Pathways; Mice; NF-E2-Related Factor 2; Oxidative Stress; Protective Agents; Tablets | 2021 |
TLR4 deficiency upregulates TLR9 expression and enhances irinotecan-related intestinal mucositis and late-onset diarrhoea.
Topics: Animals; Diarrhea; Humans; Irinotecan; Mice; Mucositis; Toll-Like Receptor 4; Toll-Like Receptor 9 | 2021 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
TU-100 exerts a protective effect against bacterial translocation by maintaining the tight junction.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacterial Translocation; Camptothecin; Cells, Cultured; Claudin-4; Cytokines; Diarrhea; Humans; Inflammation Mediators; Irinotecan; Male; Naphthoquinones; Occludin; Phytotherapy; Rats, Wistar; Tight Junctions; Toll-Like Receptors; Zonula Occludens-1 Protein | 2017 |
An evolving function of DNA-containing exosomes in chemotherapy-induced immune response.
Topics: Animals; Camptothecin; Colorectal Neoplasms; Diarrhea; DNA; Exosomes; Humans; Irinotecan; Models, Biological | 2017 |
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Topics: Adult; Aged; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged | 2017 |
UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Neutropenia; Polymorphism, Genetic | 2017 |
Specific Inhibition of Bacterial β-Glucuronidase by Pyrazolo[4,3-c]quinoline Derivatives via a pH-Dependent Manner To Suppress Chemotherapy-Induced Intestinal Toxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Diarrhea; Drug Screening Assays, Antitumor; Escherichia coli; Glucuronidase; High-Throughput Screening Assays; Humans; Hydrogen-Ion Concentration; Intestines; Irinotecan; Mice; Molecular Docking Simulation; Protective Agents; Pyrazoles; Quinolines; Structure-Activity Relationship | 2017 |
Role of regulatory T cells in irinotecan-induced intestinal mucositis.
Topics: Animals; Camptothecin; Cyclophosphamide; Cytokines; Diarrhea; Ileum; Inflammation; Intestinal Mucosa; Irinotecan; Mice; Mice, Inbred C57BL; Mucositis; Neutrophil Infiltration; Peroxidase; T-Lymphocytes, Regulatory; Th17 Cells | 2018 |
CPT-11-Induced Delayed Diarrhea Develops via Reduced Aquaporin-3 Expression in the Colon.
Topics: Animals; Aquaporin 3; Aquaporin 4; Aquaporins; Camptothecin; Celecoxib; Cell Survival; Colon; Cyclooxygenase 2; Cytokines; Diarrhea; Feces; Gene Expression; Irinotecan; Male; Mice; Nitric Oxide Synthase Type II; Rats; Rats, Wistar; RAW 264.7 Cells | 2018 |
Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.
Topics: Aged; Asthenia; Colorectal Neoplasms; Cytochrome P-450 CYP3A; Diarrhea; Female; Gene Frequency; Genetic Predisposition to Disease; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Male; Neutropenia; Pharmacogenomic Variants; Phenotype; Risk Factors; Severity of Illness Index; Topoisomerase I Inhibitors | 2018 |
Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Quality of Life; Retrospective Studies; Salivation; Syndrome; Young Adult | 2018 |
Impact of diet on irinotecan toxicity in mice.
Topics: Animals; Body Weight; Camptothecin; Carboxylesterase; Diarrhea; Diet; Fatty Liver; Glucuronidase; Irinotecan; Male; Metabolome; Mice, Inbred C57BL; Toxicity Tests | 2018 |
Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database.
Topics: Adult; Aged; Antacids; Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Cholagogues and Choleretics; Diarrhea; Female; Humans; Intestines; Irinotecan; Magnesium Oxide; Male; Middle Aged; Neutropenia; Retrospective Studies; Sodium Bicarbonate; Topoisomerase I Inhibitors; Ursodeoxycholic Acid; Uterine Cervical Neoplasms; Uterine Neoplasms | 2019 |
Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer.
Topics: Aged; Diarrhea; Drugs, Chinese Herbal; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Polymorphism, Genetic; Small Cell Lung Carcinoma | 2018 |
Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cholinergic Agents; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Prognosis; Quality of Life; Retrospective Studies; Risk Factors; Syndrome | 2019 |
Amitriptyline prevents CPT-11-induced early-onset diarrhea and colonic apoptosis without reducing overall gastrointestinal damage in a rat model of mucositis.
Topics: Amitriptyline; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Colon; Diarrhea; Disease Models, Animal; Irinotecan; Male; Mucositis; Rats; Rats, Wistar | 2019 |
Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacterial Proteins; Cell Line, Tumor; Colonic Neoplasms; Diarrhea; Escherichia coli; Eubacterium; Glucuronidase; HEK293 Cells; Humans; Irinotecan; Male; Mice, Inbred BALB C; Peptostreptococcus; Quinolines | 2019 |
Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy-induced gut toxicity in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Diarrhea; Drugs, Chinese Herbal; Female; HT29 Cells; Humans; Irinotecan; Medicine, Chinese Traditional; Mice; Mice, Inbred BALB C; Mice, Nude | 2019 |
Protective effect of curcumin against irinotecan‑induced intestinal mucosal injury via attenuation of NF‑κB activation, oxidative stress and endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Cell Line; Colorectal Neoplasms; Curcumin; Diarrhea; Disease Models, Animal; Drug Evaluation, Preclinical; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Epithelial Cells; Humans; Injections, Intraperitoneal; Intestinal Mucosa; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Oxidative Stress; Rats; Signal Transduction; Topoisomerase I Inhibitors; Treatment Outcome | 2019 |
Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Forecasting; Glucuronates; Humans; Irinotecan; Leucovorin; Leukopenia; Machine Learning; Male; Middle Aged; Models, Biological; Neutropenia; Oxaliplatin; Topoisomerase I Inhibitors | 2019 |
The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice.
Topics: Animals; Caco-2 Cells; Claudin-1; Diarrhea; Dysbiosis; Escherichia coli; Gastrointestinal Diseases; Gastrointestinal Microbiome; Humans; Intestinal Diseases; Intestinal Mucosa; Intestines; Irinotecan; Male; Mice; Mice, Inbred BALB C; Probiotics; Tight Junction Proteins | 2019 |
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia | 2013 |
UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Retrospective Studies | 2013 |
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Polymorphism, Genetic; Severity of Illness Index; Treatment Outcome | 2013 |
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2013 |
Irinotecan disrupts tight junction proteins within the gut : implications for chemotherapy-induced gut toxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Claudin-1; Diarrhea; Female; Intestinal Mucosa; Intestine, Large; Intestine, Small; Irinotecan; Occludin; Rats; Tight Junctions; Zonula Occludens-1 Protein | 2014 |
Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Cell Survival; Diarrhea; Drug Synergism; Drug Therapy, Combination; Female; Gefitinib; HEK293 Cells; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Quinazolines; RNA, Messenger; Transplantation, Heterologous | 2013 |
Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Young Adult | 2014 |
Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Records; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Severity of Illness Index; Small Cell Lung Carcinoma; Treatment Outcome; Vomiting | 2014 |
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cholesterol; Colon; Diarrhea; Disease Models, Animal; Drug Therapy, Combination; Female; Fluorouracil; Intestine, Small; Irinotecan; Liposomes; Nanoparticles; Phosphatidylcholines; Rats, Sprague-Dawley | 2014 |
Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.
Topics: Adult; Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Genome-Wide Association Study; Genome, Human; Genomics; Humans; Irinotecan; KCNQ Potassium Channels; Knowledge Bases; Male; Neoplasms; Polymorphism, Single Nucleotide; ROC Curve | 2014 |
Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea.
Topics: Animals; Camptothecin; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Diarrhea; Drug Approval; HT29 Cells; Humans; Intracellular Space; Irinotecan; Mice; Models, Molecular; Multidrug Resistance-Associated Proteins; Protein Conformation; United States; United States Food and Drug Administration | 2015 |
[Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Prospective Studies; Retrospective Studies; Small Cell Lung Carcinoma | 2015 |
Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Blood Proteins; Body Weight; Camptothecin; Cattle; Colitis; Diarrhea; Enteritis; Female; Immunoglobulins; Injections, Intraperitoneal; Irinotecan; Jejunal Diseases; Mucositis; Random Allocation; Rats | 2016 |
Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Cisplatin; Diarrhea; DNA-Binding Proteins; Endonucleases; Female; Gene Expression; Gene Frequency; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polymorphism, Genetic; Treatment Outcome | 2015 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Capecitabine; Carboplatin; Carcinoma, Neuroendocrine; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Pelvis; Radiation Injuries; Radiodermatitis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Line, Tumor; Colonic Neoplasms; Diarrhea; Fasting; Glucuronides; Irinotecan; Leukopenia; Liver; Male; Mice, Inbred BALB C; RNA, Messenger; Treatment Outcome; Tumor Burden; Weight Loss | 2016 |
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Genetic Markers; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies | 2015 |
CPT-11 activates NLRP3 inflammasome through JNK and NF-κB signalings.
Topics: Animals; Anti-Inflammatory Agents; Camptothecin; Carrier Proteins; Caspase 1; Cell Line, Tumor; Colitis; Colon; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Inflammation Mediators; Interleukin-1beta; Interleukin-8; Irinotecan; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Macrophages; Mice, Inbred C57BL; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Permeability; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Topoisomerase I Inhibitors | 2015 |
The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis.
Topics: Animals; Bacteremia; Camptothecin; Diarrhea; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Mice; Mice, Knockout; Mucositis; Myeloid Differentiation Factor 88; Peroxidase; Signal Transduction; Toll-Like Receptor 2; Toll-Like Receptor 9 | 2015 |
Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bacteria; Bacterial Proteins; Camptothecin; Cefixime; Diarrhea; Enzyme Inhibitors; Female; Flavonoids; Food-Drug Interactions; Fruit and Vegetable Juices; Gastrointestinal Microbiome; Gene Transfer Techniques; Glucuronidase; Hydrogen-Ion Concentration; Intestinal Absorption; Intestinal Mucosa; Intestines; Irinotecan; Kinetics; Malus; Mice, Inbred C57BL; Oocytes; Organic Anion Transporters; Xenopus laevis | 2016 |
A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Interleukin-6; Intestinal Mucosa; Irinotecan; Male; Mice; Mice, Inbred C57BL; Models, Animal; Mucositis; Peroxidase; Tumor Necrosis Factor-alpha | 2016 |
[Effect of Shengjiang Xiexin Decoction on the Repair of Damaged Rat Intestinal Mucosa after Irinotecan Chemotherapy].
Topics: Animals; Apoptosis; Camptothecin; Colon; Diarrhea; Drug Therapy; Drugs, Chinese Herbal; Ileum; Intestinal Mucosa; Irinotecan; Male; Rats; Rats, Sprague-Dawley; Wound Healing | 2015 |
Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic | 2016 |
A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Transforming Growth Factor beta; Young Adult | 2016 |
Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Cholera Toxin; Colon; Contrast Media; Diarrhea; Fluorouracil; Gastrointestinal Diseases; Haptoglobins; Intestinal Mucosa; Iohexol; Irinotecan; Jejunum; Male; Organoplatinum Compounds; Oxaliplatin; Permeability; Protein Precursors; Rats; Rats, Sprague-Dawley | 2016 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Retreatment; Stomach Neoplasms; Survival Rate; Vomiting; White People | 2016 |
Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report.
Topics: Animals; Camptothecin; Cancer Pain; Diarrhea; Female; Irinotecan; Naloxone; Rats; Toll-Like Receptor 4 | 2017 |
Irinotecan-induced bile acid malabsorption is associated with down-regulation of ileal Asbt (Slc10a2) in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bile Acids and Salts; Camptothecin; Cholestanetriol 26-Monooxygenase; Cholesterol 7-alpha-Hydroxylase; Colon; Diarrhea; Down-Regulation; Feces; Gallbladder; Ileum; Irinotecan; Liver; Male; Membrane Transport Proteins; Mice; Organic Anion Transporters, Sodium-Dependent; RNA, Messenger; Symporters | 2017 |
[Prevention of irinotecan hydrochloride-induced diarrhea by oral administration of Lactobacillus casei strain Shirota in rats].
Topics: Administration, Oral; Animals; Body Weight; Camptothecin; Diarrhea; Feeding Behavior; Irinotecan; Lacticaseibacillus casei; Male; Rats; Rats, Wistar; Time Factors | 2008 |
How can we ameliorate irinotecan-associated diarrhea in children with poor compliance for oral cephalosporin?
Topics: Camptothecin; Cephalosporins; Child; Diarrhea; Humans; Irinotecan; Male; Neuroblastoma; Patient Compliance | 2009 |
Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Diarrhea; Intestines; Irinotecan; Male; Rats; Rats, Wistar | 2008 |
Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Diarrhea; Escherichia coli; Feces; Gastrointestinal Tract; Gene Expression Regulation, Enzymologic; Glucuronidase; Immunohistochemistry; Intestines; Irinotecan; Jejunum; Lactobacillus; Rats; Staphylococcus | 2008 |
[A fatal case of small cell type undifferentiated carcinoma of the esophagus with sudden diarrhea and bloody discharge by CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cell Differentiation; Cisplatin; Diarrhea; Esophageal Neoplasms; Fatal Outcome; Hemorrhage; Humans; Irinotecan; Male; Middle Aged; Treatment Failure | 2008 |
The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Histocytochemistry; Irinotecan; Leukocytes; Mucositis; Rats; Saccharomyces; Weight Loss | 2009 |
Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colo
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Diarrhea; Dietary Supplements; Fatty Acids, Omega-3; Female; Fluorouracil; Glutamine; Immune Tolerance; Irinotecan; Leukocyte Count; Nutritional Status; Rats; Rats, Inbred F344; Treatment Failure; Xenograft Model Antitumor Assays | 2009 |
Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Ciprofloxacin; Colorectal Neoplasms; Diarrhea; Female; Immunity, Mucosal; Intestinal Mucosa; Irinotecan; Lymphatic Metastasis; Neoplasm Transplantation; Rats; Rats, Inbred F344; Spleen; Survival Analysis | 2009 |
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Colorectal Neoplasms; Diarrhea; DNA; DNA, Neoplasm; Ethnicity; Female; Gastrointestinal Tract; Genetic Variation; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Young Adult | 2009 |
Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Diarrhea; Feces; Female; Glucuronidase; Goblet Cells; Intestinal Mucosa; Irinotecan; Jejunum; Mucins; Mucositis; Rats | 2009 |
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.
Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Gene Frequency; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Quality of Life; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Diarrhea; Drug Therapy; Drug Therapy, Combination; Enzyme Inhibitors; Ethnicity; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Therapeutic Equivalency; Time Factors; Treatment Outcome | 2009 |
UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Retrospective Studies | 2009 |
[Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Combined Modality Therapy; Diarrhea; Exanthema; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Remission Induction; Retrospective Studies | 2009 |
Treatment of childhood sarcoma with irinotecan: bilirubin level as a predictor of gastrointestinal toxicity.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Child; Child, Preschool; Diarrhea; Female; Gastric Mucosa; Humans; Infant; Intestinal Mucosa; Irinotecan; Male; Predictive Value of Tests; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms | 2009 |
Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Glucuronidase; Glucuronosyltransferase; Intestinal Mucosa; Irinotecan; Male; Penicillin G; Rats; Rats, Gunn; Rats, Wistar; Streptomycin; Time Factors | 2011 |
[Utility of CPT-11 as salvage chemotherapy for progressive or recurrent breast cancer patients with multiple drug resistance].
Topics: Adult; Aged; Breast Neoplasms; Camptothecin; Diarrhea; Disease Progression; Drug Resistance, Multiple; Humans; Irinotecan; Middle Aged; Neutropenia; Recurrence; Salvage Therapy | 2010 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Glucuronosyltransferase; Health Surveys; Humans; Irinotecan; Mitomycin; Neutropenia; Organoplatinum Compounds; Pyridines; Risk Factors; State Medicine; United Kingdom | 2010 |
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Research Design; Survival Rate; Tomography, X-Ray Computed | 2010 |
Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria, Anaerobic; Camptothecin; Cell Line, Tumor; Colon; Crystallography, X-Ray; Diarrhea; Drug Evaluation, Preclinical; Enzyme Inhibitors; Escherichia coli; Escherichia coli Proteins; Female; Glucuronidase; Humans; Intestinal Mucosa; Irinotecan; Mice; Mice, Inbred BALB C; Models, Molecular; Prodrugs; Protein Conformation | 2010 |
[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Topics: Acneiform Eruptions; Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Diarrhea; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; ras Proteins; Rectal Neoplasms; Remission Induction; Survival Rate | 2010 |
Irinotecan injures tight junction and causes bacterial translocation in rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacterial Translocation; Camptothecin; Claudin-1; Diarrhea; Intestinal Mucosa; Irinotecan; Male; Membrane Proteins; Occludin; Permeability; Rats; Rats, Wistar; RNA, Messenger; Tight Junctions; Weight Loss | 2012 |
Barking up the wrong genome--we are not alone.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Diarrhea; Enzyme Inhibitors; Glucuronidase; Glucuronosyltransferase; Humans; Irinotecan; Mice; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs; Topoisomerase I Inhibitors | 2011 |
Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Incidence; Infusions, Intravenous; Irinotecan; Japan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Patient Selection; Polymorphism, Genetic; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Surveys and Questionnaires; Thrombocytopenia | 2011 |
Kampo medicine "Dai-kenchu-to" prevents CPT-11-induced small-intestinal injury in rats.
Topics: Animals; Apoptosis; Camptothecin; Diarrhea; In Situ Nick-End Labeling; Interferon-gamma; Interleukin-12; Interleukin-1beta; Intestine, Small; Irinotecan; Male; Medicine, Kampo; Panax; Plant Extracts; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Tumor Necrosis Factor-alpha; Zanthoxylum; Zingiberaceae | 2012 |
[Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].
Topics: Adult; Alleles; Amplified Fragment Length Polymorphism Analysis; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Uterine Cervical Neoplasms | 2011 |
Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Retrospective Studies | 2012 |
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Neutropenia; Polypharmacy; Retrospective Studies | 2013 |
A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Genome-Wide Association Study; Genotype; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies | 2013 |
[Severe diarrhea].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Camptothecin; Diarrhea; Fluorouracil; Gastrointestinal Motility; Gout Suppressants; Humans; Immunosuppressive Agents; Irinotecan; Molecular Targeted Therapy | 2012 |
Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
Topics: Alkaline Phosphatase; Animals; Biliary Tract; Body Weight; Camptothecin; Diarrhea; Drug Interactions; Genistein; Glucuronates; Glucuronides; Intestinal Mucosa; Intestines; Irinotecan; Kidney; Liver; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Probenecid; Rats; Rats, Sprague-Dawley | 2013 |
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Stomach Neoplasms | 2013 |
[Preparation and characterization of irinotecan hydrochloride loaded PEO-PPO-PEO micelles and its mechanism of decreasing drug intestinal toxicity].
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Biological Transport; Camptothecin; Cells, Cultured; Diarrhea; Dogs; Drug Carriers; Intestines; Irinotecan; Madin Darby Canine Kidney Cells; Male; Micelles; Neoplasm Proteins; Polyethylene Glycols; Propylene Glycols; Rats; Rats, Sprague-Dawley | 2012 |
[A case-control study of prevention of irinotecan-induced diarrhea: the reducing side effects of irinotecan by oral alkalization combined with control of defecation].
Topics: Administration, Oral; Antacids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Defecation; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Middle Aged; Sodium Bicarbonate; Ursodeoxycholic Acid | 2002 |
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Chi-Square Distribution; Diarrhea; Dose-Response Relationship, Drug; Female; Glucuronates; Humans; Irinotecan; Male; Middle Aged | 2002 |
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colon; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diarrhea; Dinoprostone; Drug Administration Schedule; Drug Synergism; HT29 Cells; Humans; Irinotecan; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Weight Loss; Xenograft Model Antitumor Assays | 2002 |
Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.
Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2003 |
Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.
Topics: Antidiarrheals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drugs, Chinese Herbal; Fluorouracil; Humans; Irinotecan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bacitracin; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Neomycin | 2003 |
Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats.
Topics: Administration, Oral; Animals; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Charcoal; Diarrhea; Drug Interactions; Irinotecan; Male; Models, Animal; Rats; Rats, Sprague-Dawley | 2002 |
Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bile; Biotransformation; Blood Cell Count; Body Weight; Bone Marrow; Bone Marrow Diseases; Camptothecin; Diarrhea; Infusions, Intravenous; Intestines; Irinotecan; Male; Rats; Rats, Sprague-Dawley | 2003 |
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Colon; Diarrhea; Intestine, Small; Irinotecan; Male; Neoplasm Transplantation; Rats; Severity of Illness Index | 2003 |
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Vomiting | 2003 |
Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Diarrhea; Enzyme Inhibitors; Humans; Intestines; Irinotecan; Models, Molecular; Quantitative Structure-Activity Relationship; Rabbits; Sulfonamides | 2004 |
Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Enzyme Inhibitors; Female; Glucuronidase; Intestinal Mucosa; Irinotecan; Jejunum; Lactones; Rats; Rats, Wistar; Sugar Acids | 2004 |
[Management of chemotherapy induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Loperamide; Neoplasms; Octreotide; Patient Care Management; Practice Guidelines as Topic | 2004 |
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Topics: Administration, Oral; Anti-Bacterial Agents; Antidiarrheals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Loperamide; Neomycin | 2004 |
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Leukopenia; Liver; Liver Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies | 2004 |
Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Sodium Bicarbonate; Surveys and Questionnaires | 2004 |
Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Fibroblast Growth Factor 7; Fibroblast Growth Factors; Irinotecan; Keratinocytes; Mammary Neoplasms, Animal; Rats; Survival Analysis | 2005 |
Irinotecan-induced colitis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers; Biopsy; Brain Neoplasms; Camptothecin; Colitis; Colon; Diarrhea; Glioblastoma; Humans; Ileum; Immunoenzyme Techniques; Irinotecan; Male; Topoisomerase I Inhibitors | 2005 |
Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cecal Neoplasms; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Irinotecan; Liver; Male; Neutropenia; Pharmacogenetics; Polymorphism, Genetic | 2005 |
St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Cell Count; Body Weight; Camptothecin; Chromatography, High Pressure Liquid; Diarrhea; Drug Interactions; Half-Life; Hypericum; Intestinal Diseases; Intestinal Mucosa; Irinotecan; Male; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results | 2005 |
Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colorectal Neoplasms; Diarrhea; Humans; Hydrogen-Ion Concentration; Intestines; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2005 |
Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.
Topics: Antineoplastic Agents, Phytogenic; Brain Stem Neoplasms; Camptothecin; Child; Diarrhea; Female; Glioma; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Magnetic Resonance Imaging; Polymorphism, Genetic | 2005 |
Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Enzyme Inhibitors; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Pharmacogenetics; Polymorphism, Genetic; Prodrugs; Promoter Regions, Genetic; Topoisomerase I Inhibitors | 2005 |
[CPT-11-induced diarrhea treated with indisetron hydrochloride--a case report].
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Pyrazoles; Quality of Life; Stomach Neoplasms | 2005 |
[Management of chemotherapy-induced mucositis and diarrhea].
Topics: Allopurinol; Antineoplastic Agents; Camptothecin; Diarrhea; Free Radical Scavengers; Histamine H2 Antagonists; Humans; Irinotecan; Neoplasms; Proton Pump Inhibitors; Quality of Life; Stomatitis | 2006 |
A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Neutropenia; Paclitaxel; Platinum; Survival Rate; Time Factors | 2005 |
Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
Topics: Animals; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Enzyme Inhibitors; Flavonoids; Glucuronidase; Intestines; Irinotecan; Male; Medicine, Kampo; Penicillins; Rats; Rats, Wistar; Streptomycin | 2006 |
Intestinal microflora and digestive toxicity of irinotecan in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cecum; Colon; Diarrhea; Dose-Response Relationship, Drug; Ileum; Intestinal Mucosa; Intestines; Irinotecan; Jejunum; Mice; Mice, Inbred C3H; Microscopy, Electron, Scanning; Necrosis; Specific Pathogen-Free Organisms; Survival Analysis; Time Factors | 2006 |
Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar).
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics | 2006 |
Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Blood Proteins; Camptothecin; Cell Line, Tumor; Diarrhea; Drug Interactions; Glucuronides; Hydrolysis; Intestines; Irinotecan; Leukocyte Count; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Thalidomide; Tumor Necrosis Factor-alpha | 2006 |
Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.
Topics: Administration, Oral; Adsorption; Animals; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Carbon; Chromatography, High Pressure Liquid; Diarrhea; Hydrogen-Ion Concentration; Intestinal Mucosa; Irinotecan; Male; Oxides; Rats; Rats, Wistar | 2007 |
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Colonic Neoplasms; Colony-Forming Units Assay; Dacarbazine; Diarrhea; Drug Synergism; Enzyme Inhibitors; Intestinal Diseases; Irinotecan; Organic Chemicals; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topoisomerase I Inhibitors; Tumor Burden | 2006 |
A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Blood Proteins; Bone Marrow; Caco-2 Cells; Camptothecin; Diarrhea; Hepatocytes; Humans; Intestines; Irinotecan; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thalidomide; Tumor Necrosis Factor-alpha; Weight Loss | 2006 |
The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Diarrhea; Female; Glucuronides; Glucuronosyltransferase; Intestines; Irinotecan; Male; Rats; Rats, Gunn | 2007 |
St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cytokines; Diarrhea; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Hypericum; Intestinal Mucosa; Irinotecan; Male; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley | 2006 |
Searching for the Holy Grail of oncology.
Topics: Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Diarrhea; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Assessment | 2006 |
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
Topics: Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide | 2007 |
Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Bacterial Typing Techniques; Biodiversity; Camptothecin; Colon; Colony Count, Microbial; Diarrhea; Feces; Female; Gastric Mucosa; Gastrointestinal Tract; Histocytochemistry; Intestinal Mucosa; Irinotecan; Jejunum; Rats; Rats, Inbred Strains; Stomach; Time Factors | 2007 |
St. John's wort and irinotecan-induced diarrhea.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Interactions; Humans; Hypericum; Irinotecan; Phytotherapy; Plant Extracts | 2007 |
Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Assessment; Risk Factors | 2007 |
[Chemotherapy for elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Vomiting, Anticipatory | 2007 |
Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Diarrhea; Fibroblast Growth Factors; Gastroenteritis; Irinotecan; Mucositis; Rats; Rats, Inbred Strains | 2007 |
Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Cisplatin; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies | 2007 |
Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Crigler-Najjar Syndrome; Diarrhea; Glucuronosyltransferase; Hyperbilirubinemia; Intestines; Irinotecan; Rats; Rats, Gunn; Rats, Wistar | 2008 |
Chemotherapy-induced mucositis: focusing on diarrhea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Camptothecin; Dehydration; Diarrhea; Fluorouracil; Gastric Mucosa; Gastrointestinal Tract; Humans; Infusions, Intravenous; Intestinal Absorption; Intestinal Mucosa; Irinotecan; Leucovorin; Loperamide; Mice; Mucositis; Organoplatinum Compounds; Rats | 2007 |
Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemokines; Diarrhea; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Injections, Intraperitoneal; Interleukin-1beta; Intestine, Small; Irinotecan; Male; Mice; Mucositis; Pentoxifylline; Peroxidase; Thalidomide; Tumor Necrosis Factor-alpha | 2008 |
Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Diarrhea; Fluorouracil; Granulomatosis with Polyangiitis; Hemorrhage; Humans; Irinotecan; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 2007 |
Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Prodrugs; Promoter Regions, Genetic | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2007 |
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Coloring Agents; Cytokines; Diarrhea; Digestive System; Eosine Yellowish-(YS); Female; Fluorescent Dyes; Gastric Mucosa; Hematoxylin; Immunohistochemistry; Intestinal Mucosa; Irinotecan; Jejunum; Mouth Mucosa; Mucositis; NF-kappa B; Rats | 2008 |
Establishment of a single-dose irinotecan model of gastrointestinal mucositis.
Topics: Animals; Body Weight; Camptothecin; Diarrhea; Disease Models, Animal; Female; Irinotecan; Mucositis; Neoplasm Transplantation; Organ Size; Rats; Survival Rate | 2007 |
Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor.
Topics: Animals; Camptothecin; Colonic Neoplasms; Diarrhea; Diet; Fatty Acids, Omega-3; Female; Food-Drug Interactions; Glutamine; Irinotecan; Oligosaccharides; Probiotics; Rats | 2007 |
Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Colon; Colonic Neoplasms; Cytoprotection; Diarrhea; Female; Glutamine; Irinotecan; Neoplasms, Experimental; Rats | 2008 |
[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Case-Control Studies; China; Colorectal Neoplasms; Diarrhea; Fluorouracil; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Young Adult | 2007 |
Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Atropine; Camptothecin; Cecum; Diarrhea; Drugs, Chinese Herbal; Enzyme Inhibitors; Flavonoids; Glucuronidase; Intestines; Irinotecan; Male; Rats; Rats, Wistar | 1995 |
Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cecum; Cisplatin; Diarrhea; Enzyme Inhibitors; Hyperplasia; Ileum; Intestinal Mucosa; Irinotecan; Male; Mice; Mucins; Proliferating Cell Nuclear Antigen; Serotonin; Topoisomerase I Inhibitors; Vasoactive Intestinal Peptide | 1995 |
[Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats].
Topics: Animals; Antidiarrheals; Antineoplastic Agents, Phytogenic; Body Water; Camptothecin; Diarrhea; Intestinal Absorption; Irinotecan; Male; Rats; Rats, Wistar | 1995 |
A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Neprilysin; Randomized Controlled Trials as Topic; Thiorphan | 1995 |
[Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11)].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 1994 |
Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats.
Topics: Animals; Camptothecin; Cholinesterase Inhibitors; Defecation; Diarrhea; Dogs; Injections, Intravenous; Irinotecan; Male; Rats; Receptors, Cholinergic; Topoisomerase I Inhibitors; Vomiting | 1993 |
Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Diarrhea; Enterocolitis; Injections, Intraperitoneal; Intestinal Mucosa; Intestines; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude | 1993 |
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Liver; Lung; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction; Survival Analysis | 1996 |
Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Diarrhea; Glucuronidase; Intestines; Irinotecan; Male; Rats; Rats, Wistar | 1996 |
Re:Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Atrophy; Camptothecin; Cecum; Cisplatin; Diarrhea; Ileum; Intestinal Mucosa; Irinotecan; Mice | 1996 |
Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colon; Diarrhea; Dinoprostone; Enzyme Inhibitors; Intestinal Absorption; Intestine, Large; Irinotecan; Male; Rats; Rats, Wistar; Topoisomerase I Inhibitors; Water | 1997 |
Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Diarrhea; Dinoprostone; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Eating; Intestinal Absorption; Irinotecan; Male; Rats; Rats, Wistar; Topoisomerase I Inhibitors; Water; Weight Gain | 1997 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Etoposide; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Risk Assessment | 1998 |
Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Colorectal Neoplasms; Diarrhea; Disease Models, Animal; Drug Interactions; Duodenum; Female; Interleukin-15; Intestinal Mucosa; Irinotecan; Paraffin Embedding; Rats; Rats, Inbred F344 | 1998 |
Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Bacteria; Camptothecin; Diarrhea; Enzyme Inhibitors; Glucuronidase; Injections, Intravenous; Intestine, Large; Intestine, Small; Irinotecan; Male; Penicillins; Rats; Rats, Wistar; Streptomycin | 1998 |
Bradycardia induced by irinotecan: a case report.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bradycardia; Camptothecin; Cholinergic Agents; Colonic Neoplasms; Diarrhea; Electrocardiography; Humans; Irinotecan; Male | 1998 |
Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in an aged patient; and CPT-11 pharmacokinetics.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Salvage Therapy | 1999 |
Continual reassessment methods in phase I trials of the combination of two drugs in oncology.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Humans; Irinotecan; Likelihood Functions; Neoplasms; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 1999 |
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms | 1999 |
Glutamine for irinotecan diarrhea.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Glutamine; Humans; Irinotecan; Male; Middle Aged; Rectal Neoplasms | 2000 |
Moving beyond fluorouracil for colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia | 2000 |
Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biliary Tract; Camptothecin; Cecum; Diarrhea; Drug Administration Schedule; Glucuronates; Ileum; Intestinal Mucosa; Irinotecan; Male; Rats; Rats, Sprague-Dawley | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality of Life | 2001 |
Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Octreotide; Prospective Studies; Treatment Failure | 2001 |
Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.
Topics: Animals; Camptothecin; Diarrhea; Digestive System; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Incidence; Irinotecan; Male; Mice; Mice, Inbred BALB C; Rats; Rats, Wistar; Sarcoma, Experimental; Tissue Distribution | 2001 |
Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Octreotide; Treatment Outcome | 2001 |
Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Body Surface Area; Camptothecin; Colorectal Neoplasms; Diarrhea; Glucuronosyltransferase; Humans; Irinotecan | 2002 |
Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carboxylic Acids; Cell Cycle; Cell Division; Cricetinae; Diarrhea; Glucuronides; HT29 Cells; Humans; Hydrogen-Ion Concentration; Intestinal Mucosa; Intestines; Irinotecan; Lactones; Male; Mesocricetus; Sodium Bicarbonate | 2002 |
Thalidomide and irinotecan-associated diarrhea.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Immunosuppressive Agents; Irinotecan; Lung Neoplasms; Rectal Neoplasms; Thalidomide | 2002 |